ARTP statement on pulmonary function testing 2020. by Sylvester, KP et al.
  1Sylvester KP, et al. BMJ Open Resp Res 2020;7:e000575. doi:10.1136/bmjresp-2020-000575
To cite: Sylvester KP, 
Clayton N, Cliff I, et al. ARTP 
statement on pulmonary 
function testing 2020. 
BMJ Open Resp Res 
2020;7:e000575. doi:10.1136/
bmjresp-2020-000575
Received 6 February 2020
Revised 11 February 2020
Accepted 14 February 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Karl Peter Sylvester;  
 karl. sylvester@ nhs. net
ARTP statement on pulmonary function 
testing 2020
Karl Peter Sylvester,1,2 Nigel Clayton,3 Ian Cliff,4 Michael Hepple,4 Adrian Kendrick,5 
Jane Kirkby,6 Martin Miller,7 Alan Moore,8 Gerrard Francis Rafferty,9 Liam O'Reilly,10 
Joanna Shakespeare,10 Laurie Smith   ,6,11 Trefor Watts,12 Martyn Bucknall,13 
Keith Butterfield14
Guidelines
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
AbstrAct
The Association for Respiratory Technology & Physiology 
(ARTP) last produced a statement on the performance 
of lung function testing in 1994. At that time the focus 
was on a practical statement for people working in lung 
function laboratories. Since that time there have been 
many technological advances and alterations to best 
practice in the measurement and interpretation of lung 
function assessments. In light of these advances an update 
was warranted. ARTP, therefore, have provided within 
this document, where available, the most up- to- date and 
evidence- based recommendations for the most common 
lung function assessments performed in laboratories 
across the UK. These recommendations set out the 
requirements and considerations that need to be made 
in terms of environmental and patient factors that may 
influence both the performance and interpretation of lung 
function tests. They also incorporate procedures to ensure 
quality assured diagnostic investigations that include those 
associated with equipment, the healthcare professional 
conducting the assessments and the results achieved 
by the subject. Each section aims to outline the common 
parameters provided for each investigation, a brief 
principle behind the measurements (where applicable), and 
suggested acceptability and reproducibility criteria.
Foreword
The Association for Respiratory Technology 
& Physiology (ARTP) was at the forefront of 
producing useable and readable guidelines 
on how to undertake lung function testing.1 
The emphasis then was on a practical state-
ment that would be a helpful reference for 
people working in lung function testing. The 
ARTP have now produced this revised and 
expanded statement on lung function testing 
with the emphasis still being that it can be 
used in lung function laboratories as a means 
to improve the quality and reliability of the 
results achieved by patients.
ARTP have provided within this docu-
ment, where available, the most up- to- date 
and evidence- based recommendations for 
the most common lung function assess-
ments performed in laboratories across the 
UK. These recommendations set out the 
requirements and considerations that need 
to be made in terms of environmental and 
patient factors that may influence both the 
performance and interpretation of lung 
function tests. They also incorporate proce-
dures to ensure quality assured diagnostic 
investigations that include those associated 
with equipment, the healthcare professional 
conducting the assessments and the results 
achieved by the subject. Each section aims to 
outline the common parameters provided for 
each investigation, a brief principle behind 
the measurements (where applicable), and 
suggested acceptability and reproducibility 
criteria.
It has been over 10 years since the compre-
hensive series of joint American Thoracic 
Society/European Respiratory Society (ATS/
ERS) statements on lung function testing.2–5 
One of the problems arising from those has 
been the view that patients either pass or fail 
the criteria set down in those statements. 
This was not the intention of the group who 
prepared those statements. Aspects of this 
have been addressed in the 2019 update of 
the spirometry statement.6 Also an updated 
standard for single- breath carbon monoxide 
(CO) uptake transfer factor was published 
in 20177 which, in particular, incorporated 
changes in gas analyser technology.
We have been clear that the reason for 
setting out the ARTP view on lung function 
testing is to help ensure that each individual 
patient has the greatest chance of achieving 
their best result on the day of their tests. In 
no sense should a patient ever pass or fail the 
test session.
The statements in these guidelines about 
criteria that should be satisfied when under-
taking lung function testing outline goals 
and drivers that lead to ensuring a patient 
achieves the best results possible on the day of 
their test. If a patient does not meet all these 
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criteria, it does not invalidate any of the results obtained. 
It may just mean that those results may not be a reliable 
indicator of what the patient might be able to achieve. 
However, the results produced may still provide sufficient 
information to support any clinical decision- making with 
the proviso that a repeat test at another test session might 
yield a different result.
We hope this document proves to be accessible and 
sufficiently comprehensive that it will assist pulmonary 
function laboratories in delivering the best outcomes for 
their patients.
Dr Karl Sylvester, Past Chair, ARTP 2020
Key messages
 ► This statement outlines the latest best practice guid-
ance for the performance of the most common lung 
function assessments in a respiratory physiology 
department
 ► Reccomendations are provided on how to undertake 
these assessments safely, to quality assured standards 
and utilising the most suitable reference values avail-
able for the interpretation of results
GenerAl procedures
The subject should be correctly prepared for the tests 
and various subject details recorded.
The subject’s age is recorded (to one decimal place), 
height to the nearest 0.5 cm and weight to the nearest 
0.5 kg (wearing indoor clothes without shoes).
Standing height is a key measurement as it is commonly 
used to estimate predictive values for the majority of 
indices used in evaluating the pulmonary function of 
both children and adults.
 ► Standing height: This should be measured without 
shoes, with the feet together, heels, scapulae and 
buttocks against the stadiometer/wall, standing as 
tall as possible with the eye level looking straight 
ahead (Frankfurt plane) using an accurate measuring 
device.5 Because height increases with increasing age 
during childhood and decreases with increasing age 
in adulthood, particularly in older subjects, height 
should ideally be measured on every occasion when 
measurements of lung function are being made to 
ensure that accurate diagnosis and classification of 
disease severity are maintained.8–11
However, standing height measurements may not be 
reliable in patients with thoracic skeletal deformities, 
the elderly or in patients who have certain syndromes, 
such as achondroplasia12 and osteogenesis imperfecta.13 
These individuals typically have a lower standing height 
than expected, which may result in an overestimation of 
their pulmonary function status, and consequently may 
affect decisions about their treatment.
 ► Arm span: For patients with a deformity of the 
thoracic cage, such as a kyphoscoliosis, the arm span 
can be measured. This is the distance between the 
tips of the middle fingers of maximally extended hori-
zontal arms—fingertip to fingertip—while standing 
in stockinged feet against a wall. Traditionally, this has 
been calculated as the arm span/1.03 for males and 
arm span/1.01 in females. However, it has recently 
been observed that differences between arm span 
and standing height are related to ethnicity, sex and 
age.14 The calculations are complex, but a program 
that estimates standing height from arm span, age 
and ethnicity can be downloaded from the spirXpert 
website (https:// spirxpert. ers- education. org/ en/ 
download/ armspan- to- height- software/).
Some patients may not be able to extend their arms, so 
alternatives are needed.
 ► Demi- span: This is measured with the subject standing 
upright with their back straight, arms extended side-
ward at 90° to the torso, fingers stretched, and the 
arm rested against a wall to avoid forward or backward 
bending. Arm span is twice the measured demi- span.
 ► Ulnar length: This has been reported as an alternative. 
Ulna length can be obtained in sitting position with 
the left forearm resting comfortably on a table. The 
palm faces downwards, and the fingers are extended 
together. The elbow should be bent at 90°–110°. 
The proximal end of the ulna is located by palpating 
along its length. The tip of the styloid process is felt 
at the wrist by palpating down the length of the bone 
distally until its end is felt. Generally, a set of callipers 
is used to obtain an accurate measure. As with demi- 
span and arm span, there is a choice of equations, 
some of which contain age and ethnicity as important 
factors.15 Which equation is used should be stated on 
the report form.
 ► Knee height: This is generally used in nutrition studies 
in the elderly,16 17 where standing height may be diffi-
cult to obtain easily.18 Knee height is the distance 
between the lower edge of the heel and the upper 
part of the knee (just above the kneecap) measured 
with the subject in sitting position, legs hanging over 
the edge of the chair, and knees and hips bent at 90°. 
The tape measure is placed along the outside of the 
leg, parallel to the major axis of the tibia.
The gender of a subject is the way they portray them-
selves within society and may differ from their birth 
sex. For the purposes of assessing lung function, it is 
the subject’s birth sex (more correctly, the biological 
sex through puberty) that determines the size of their 
lungs. Birth sex should therefore be used in the context 
of prediction of lung function and not gender. Failure 
to address this correctly may mean a transgender patient 
will be incorrectly assessed/diagnosed.19
The operator should record the type and dosage of any 
relevant medication that could influence the outcome of 
investigations, inclusive of inhaled, oral or intravenous 
respiratory medication and when the drugs were last 
administered.
Ideally the subject should be asked to do the following20:
 ► Avoid smoking on the day of the test.7
 ► Not consume alcohol for at least 4 hours prior to the 
test.
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Table 1 Recommended washout intervals prior to methacholine challenge test
Drug type Example Washout interval
Muscarinic antagonists SAMA (eg, ipratropium) 12 hours
LAMA (eg, tiotropium) 7 days
Beta- agonists SABA (eg, salbutamol) 6 hours
LABA (eg, salmeterol) 24 hours
uLABA (eg, olodaterol) 48 hours
Xanthines Theophylline Not necessary
Inhaled glucocorticosteroid Single dose (eg, budesonide) Not necessary
Stable dose (eg, budesonide) Unknown
Leukotriene receptor antagonists Single dose or up to 1 week (eg, montelukast) Not necessary
Stable dose Unknown
Antihistamines (eg, diphenhydramine, desloratadine) Not necessary
Combination therapies
(limited or no data)
ICS/LABA (eg, fluticasone/formoterol) 24 hours
ICS/uLABA (eg, fluticasone/vilanterol) 48 hours
LAMA/LABA
(eg, glycopyrronium/indacaterol)
7 days
Reproduced from Davis et al.21
ICS, inhaled corticosteroids; LABA, long- acting beta- agonist; LAMA, long- acting muscarinic antagonist; SABA, short- acting beta- agonist; 
SAMA, short- acting muscarinic antagonist; uLABA, ultra- long- acting beta- agonist.
 ► Avoid vigorous exercise for at least 30 min prior to the 
test.
 ► Avoid wearing clothing which substantially restricts 
full chest and abdominal expansion.
 ► Refrain from eating a substantial meal for at least 
2 hours prior to the test.
These requests should be made at the time of making 
the appointment. On arrival all the points should be 
checked and any deviations from them recorded.
At the start of the tests the ambient temperature and 
barometric pressure (PBOX) should be recorded to enable 
all volume measurements to be adjusted and reported at 
body temperature and pressure saturated (BTPS).
withholding bronchodilators
Subjects should arrive for investigations on their usual 
medication unless being assessed for bronchodilator 
responsiveness or bronchial provocation testing when 
the subject should be asked to withhold some of their 
inhaled medication, as outlined in table 1.
When considering the period of time for a medication 
to be inactive in the airways, it must be borne in mind 
that there will be no single point duration of activity that 
applies to every individual due to many confounding 
factors, which include the number of available recep-
tors in the airways, the size of the individual, the mech-
anism, route and efficiency of delivery of previous doses 
of the drug. Pharmacokinetic studies in patients suggest 
that, for example, in salbutamol, 4–6 hours is the time 
required for lung function to return to predrug admin-
istration. Currently the generally accepted withhold 
times are those recommended in the ATS/ERS 2005 
guidelines4 of 4 hours for short- acting beta- agonists and 
12 hours for long- acting beta- agonists; however, many 
new compounds have been introduced recently.
By studying airway smooth muscle contraction using 
methacholine challenge testing, Davis et al21 showed the 
relative duration of bronchoprotection for a variety of 
commonly used respiratory medications. This gives some 
guide for the appropriate withhold times to establish 
clearance of these medications prior to testing when a 
baseline test (ie, without the support of medication) is 
required.
When asking patients to withhold medication, careful 
consideration should always be made regarding with-
holding any medication, and this should remain the 
responsibility of the healthcare professional requesting an 
assessment following administration of any medication.
There will be instances where this is clinically inappro-
priate or unsafe and treatment withdrawal will need to be 
agreed by the referring clinician. Local protocols should 
address this.
Indications for lung function testing
There is no specific evidence to absolutely contraindi-
cate the performance of lung function. There are occa-
sions when optimum results will not be obtained due 
to pre- existing conditions and this should be stated on 
the patient’s report, since the possible consequences of 
producing suboptimal results for a patient, for example, 
refusal for surgery based on apparently low lung func-
tion, should be based on poor physiology and not down 
to impaired effort.
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Table 2 Indications for testing Adapted from Cotes
Category Use
Medical 
diagnosis
 ► Measure the effects of disease on 
respiratory function.
 ► Follow the course of a disease affecting 
respiratory function.
 ► Evaluate signs, symptoms or laboratory 
findings.
 ► Physical fitness, selection or evaluation in 
health and disease.
 ► To reassure the patient and/or the physician.
Surgery  ► Preoperative risk evaluation for anaesthetic 
and surgery.
 ► Postoperative assessment of surgery, 
particularly thoracic surgery.
Disability 
evaluation
 ► Industrial medical.
 ► Government compensation laws.
 ► Personal injury lawsuit.
 ► Other legal purposes e.g, failure to provide a 
breath test.
 ► Epidemiology.
Research  ► Clinical trials.
Adapted from Cotes.174
Each case will have its individual risk versus benefit 
to the performance of lung function, and therefore a 
discussion should take place among relevant healthcare 
professionals to determine the most appropriate and safe 
way to proceed (table 2).
contraindications for lung function testing
The majority of contraindications for pulmonary func-
tion testing are relative and depend on balancing the risk 
of any possible complications with the clinical need for 
the result. The general list of conditions held to neces-
sitate caution is generally accepted to be the following:
 ► Haemoptysis of unknown origin (forced expiratory 
manoeuvre may aggravate the underlying condition).
 ► Pneumothorax.
 ► Unstable cardiovascular status (forced expiratory 
manoeuvre may worsen angina or cause changes in 
blood pressure) or ‘recent’ myocardial infarction or 
pulmonary embolus.
 ► Thoracic, abdominal or cerebral aneurysms (danger 
of rupture due to variation in thoracic pressure).
 ► ‘Recent’ eye surgery (eg, cataract).
 ► Presence of an acute illness or symptom that 
might interfere with test performance (eg, nausea, 
vomiting).
 ► Recent thoracic or abdominal surgery.
This list was mostly based on expert opinion22; however, 
an update to these contraindications23 examined each 
of these in closer detail and advocates that some of the 
conditions that it had previously been suggested needed 
a 6- week recovery period prior to testing could be safe 
after less than 3 weeks.
consent
Consent is the principle that a person must give permis-
sion before they receive any type of medical treatment, 
test or examination. Consent is an essential component 
of both medical ethics and human rights law.
Consent is only valid if it is voluntary and informed. 
Importantly the person giving consent must have the 
capacity to make the decision. The following are the 
three keywords in the previous sentence:
 ► Voluntary: the decision to either consent or not to 
consent must be made by the person themselves and 
must not be influenced by pressure from clinical staff, 
friends or family.
 ► Informed: the person must be given all of the informa-
tion in terms of what is involved, including the bene-
fits and risks, and what happens if the test/treatment 
does not proceed.
 ► Capacity: the person must be capable of giving 
consent, which means they understand the informa-
tion given to them, and they can use it to make an 
informed decision.
If an adult has the capacity to make a voluntary and 
informed decision to consent to or refuse a particular test 
or treatment, their decision must be respected.
Consent can be given through the following:
 ► Verbally: for example, by saying they are happy to have 
a test.
 ► In writing: for example, by signing a consent form for 
a complex test that may carry increased risks.
Someone could also give non- verbal consent, as long as 
they understand the treatment or examination about to 
take place, for example, holding out an arm for a blood 
test.
Consent should be given to the healthcare profes-
sional directly responsible for the person’s current tests 
or treatment. If the subject changes their mind at any 
point before the test commences, or even during the test, 
such as a cardiopulmonary exercise test, the test must be 
stopped.
People aged 16 or over are entitled to consent to their own 
treatment, and this can only be over- ruled in exceptional circum-
stances. Like adults, young people (aged 16 or 17) are 
presumed to have sufficient capacity to decide, unless 
there is significant reason indicating to the contrary.
Children under the age of 16 can consent if they are 
believed to have enough intelligence, competence and 
understanding to fully appreciate what is involved in 
their treatment. This is known as being ‘Gillick compe-
tent’. If the child is not Gillick competent then someone 
with ‘parental responsibility’ can consent for them. This 
could be the following:
 ► The child’s mother or father.
 ► The child’s legally appointed guardian.
 ► A person with a residence order concerning the child.
 ► A local authority designated to care for the child.
 ► A local authority or person with an emergency protec-
tion order for the child.
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The person with parental responsibility must have the 
capacity to give consent.
preparation
Subjects should be as relaxed as possible before and 
during the tests and should be seated for 5–10 min prior 
to testing.
For reasons of safety the patient should not stand 
during any investigations but should sit upright in a chair 
with arms with the equipment at the appropriate height, 
angle and distance.
Subjects should be asked to loosen tight- fitting 
clothing. Dentures should normally be left in place; if 
they are loose they may interfere with performance and 
are then best removed.
The purpose and nature of the test should be clearly 
and fully explained to the subject. The subject should be 
sitting comfortably with both feet flat on the floor and in 
an upright posture. The mouthpiece assembly should be 
adjusted to an appropriate height so that the chin is at 
90° horizontal to the chest, thereby ensuring a straight 
upper airway. The tests are usually performed wearing 
tight- fitting noseclips to avoid unnecessary leaks.
When patients return for repeat testing, then ideally 
the time of day, the equipment and the operator should 
be the same.
order of testing
There is no evidence for a usual order for performing 
lung function tests. However, healthcare professionals 
should be mindful of the influence manoeuvres may have 
on subsequent investigations.
For example:
 ► Performance of nitrogen washout prior to gas transfer.
 ► Potential for dynamic airway obstruction on repeat 
dynamic manoeuvres.
 ► The timing of bronchodilator administration for 
reversibility assessment.
 ► Undertaking gas transfer (CO) test after bronchodi-
lator administration.
There should be appropriate delays between tests as 
indicated in the subsequent sections in this document. 
Department protocols will dictate the usual order of 
testing, although the clinical drivers for undertaking the 
investigations may help determine the most appropriate 
approach to the tests and their order.
Infection control
Infection control presents a number of issues within a 
testing laboratory, and different centres will be provided 
with different solutions to the same problems. The 
degree of risk of cross- infection of patients via lung func-
tion testing equipment remains unquantified. Based on 
currently available evidence, there is little justification 
for elaborate precautions for the majority of patients 
attending the laboratory, but attention to appropriate 
routine cleaning and disinfection protocols is impor-
tant.2 24
There should be local policies, including cleaning 
protocols, which have been approved by local cross- 
infection teams.
Disinfection and sterilisation can be achieved by a 
variety of methods, although chemical methods should 
be used with caution for health and safety reasons. 
Identification of factors increasing the susceptibility or 
infectivity of particular patients, such as those with cystic 
fibrosis (CF), is important in determining appropriate 
precautions, and these precautions may be advised by 
national or international recommendations in relation 
to the specific disease.
Where patients are known to be infectious or are 
immunocompromised, additional precautions such 
as using a barrier filter is appropriate. Until further 
studies are able to quantify the degree of risk of cross- 
infection that lung function test equipment poses, the 
recommendations given in the 2003 review of Kendrick 
et al24 provide a practical approach to dealing with this 
problem.
QuAlIty AssurAnce
Good quality assurance systems will ensure that a robust 
series of checks—before, during and after the patient’s 
visit—will ensure that the results generated will be as 
accurate and precise as possible. This ensures that the 
results reported are the best possible representation of 
the subject’s status. Good repeatability of the measure-
ments within a visit and reproducibility between visits 
(whether at the same or different establishments) help to 
ensure that lung function results are reliable for clinical 
decision- making.
The quality of the output of any particular laboratory 
is a product of several factors, all of which would be 
demonstrable by good governance with regard to poten-
tial sources of error.25
The following are the principal sources of error:
 ► Procedures and protocols.
 ► Equipment.
 ► Operator.
 ► Patient.
Departments may want to demonstrate their compli-
ance with governance standards by registering with a 
recognised accreditation scheme. In the UK this would be 
the Improving Quality In Physiological Services (IQIPS) 
programme.26
IQIPS is a system of mandatory accreditation in the 
UK, for physiological services, including respiratory and 
sleep services. This involves completion of an online 
‘Traffic Light Ready’ tool followed by an onsite visit and 
is recognised by the Care Quality Commission. IQIPS can 
also act as a service improvement tool, to highlight areas 
where services are below the required standard to facili-
tate service improvement.
6 Sylvester KP, et al. BMJ Open Resp Res 2020;7:e000575. doi:10.1136/bmjresp-2020-000575
Open access
procedures and protocols
The standards set out in the various sections of this docu-
ment enable a consistent approach to each diagnostic 
procedure and thus reduce variability in performance of 
the test. Standard operating procedures (SOPs) should 
be available and regularly updated to record local proce-
dures and the rationale behind any deviation from 
standard practice. These documents should be ratified 
by local governance mechanisms. SOPs may require addi-
tional supporting documentation such as Risk or Control 
of Substances Hazardous to Health assessments.27
equipment
Equipment used in routine diagnostic procedures should 
only be used according to manufacturers’ recommenda-
tions and must meet local legislative regulations for use in 
healthcare. Patients should not be tested on systems with 
any modifications to equipment or alteration to proce-
dures unless they have been risk- assessed and approved 
through local governance mechanisms before use.
Because reference values rely on accurate measure-
ment of patient demographics, it is important that 
equipment other than the diagnostic machines are also 
checked for accuracy, for example, stadiometers and 
weighing scales. Barometers and thermometers used to 
calculate the BTPS correction factors applied also need 
to be maintained and verified.
Planned preventative maintenance
Routine day- to- day maintenance is essential to keep 
equipment in prime condition. A planned preventative 
maintenance (PPM) schedule specifies what intervention 
is needed at what interval. The system used to track PPM 
(commonly a log book) should identify when an inter-
vention is due and then when it was performed and by 
whom. Items recorded will depend on the actual equip-
ment in use but must include manufacturer’s service visits 
and replacement of parts, including software updates.
Servicing of equipment should be carried out at the 
frequency recommended by the manufacturer using 
appropriately qualified and authorised personnel.
Following service visits the authorised agent should 
certify that the equipment is working to specification 
before it is returned to clinical use.
Calibration/Verification
Regular calibration/verification should be performed 
at a frequency appropriate to the characteristics of the 
instrument being used. In most applications this would 
be at least daily or prior to a testing session if used less 
than daily. See each separate section for test- specific 
recommendations.
Calibration/verification needs to be augmented by a 
set of physiological control checks (BioQC) which check 
all aspects of the system (operator, procedure and equip-
ment). Laboratory time needs to be set aside for each 
piece of equipment to be tested in this way at least weekly. 
BioQC programmes improve measurement quality28 and 
should be a mandatory part of any laboratory’s routine.
Elements of a BioQC programme
Subjects volunteering for a BioQC programme must give 
written consent to participate and share their data for this 
purpose. It should be borne in mind that confidentiality 
of data collected as part of quality assurance procedures 
is subject to the same rules as patient confidentiality.
Good control of all the quality assurance factors 
discussed above should ensure minimal error in repro-
ducibility of measurements. Maintaining a regular 
programme of BioQC on stable subjects can help iden-
tify abnormal variability in any particular combination of 
operator, procedure and equipment.
A BioQC programme for pulmonary function tests 
should incorporate measuring all indices at least weekly 
on a subject who is free from any lung disease and can 
produce stable results over time. Ideally more than one 
subject should be used.
Many lung function systems now record calibrations 
and even biological control (BioQC) procedures within 
the equipment’s own software—it is unnecessary to dupli-
cate such events in a PPM log, but all contemporaneous 
sources will need to be reviewed if trying to trace the 
source of a fault discovered later.
For each index being monitored obtain 10 measure-
ments over 10 sessions on consecutive working days, 
record the mean and upper and lower limit (mean +2 SD, 
mean −2SD, respectively) for each index. This establishes 
the upper and lower limits for each index within which 
all subsequent values should fall. On subsequent weekly 
measurements of the BioQC, obtain the measurements 
for each index and check these are within these previ-
ously defined limits. If they fail this check then the equip-
ment should be taken out of service until the source of 
the abnormality can be identified. Best practice would be 
to run at least one other BioQC on a different subject 
to ensure that the error is with the equipment and not 
the individual. At least once every 2 years the 10 refer-
ence measurements need to be repeated to generate new 
limits of agreement.
Any significant change to the equipment or software 
being used should prompt performance of BioQC checks 
to monitor the stability of measurements. During routine 
testing sessions a BioQC may be needed to check the 
validity of an instrument which is in doubt when a simple 
calibration/verification check does not persuade the 
operator that it is working correctly.
Facilities
Lung function laboratories should maintain facilities 
in accordance with recommendations published by the 
ARTP,29 which also summarise relevant legislative issues. 
Where departments do not meet these recommenda-
tions, this should be highlighted to senior management 
and clinical governance teams as potential safety risks to 
both patients and staff.
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personnel
Leadership
A senior regulated, experienced physiologist (Band 7 
and above) should have responsibility for all aspects of 
the lung function service. They may have postgraduate 
qualifications, be able demonstrate competence in all 
aspects of lung function measurement and show evidence 
of continuing professional development. They may also 
have research skills.
Operator competency
A variety of healthcare professionals undertake meas-
urements of respiratory physiology. This is particu-
larly evident when considering the range of healthcare 
settings in which the measurement of lung function is 
performed.
It is widely recognised that formal classroom- style 
training alone does not ensure practical competency. It 
is expected that all healthcare professionals performing 
measurements of spirometry and/or full lung function 
testing have an appropriate qualification of competency 
or can demonstrate equivalence. Professional training 
programmes are often provided by regulatory groups/
governing bodies. The current ARTP professional exam-
inations ( www. artp. org. uk) are a UK example of profes-
sional competency. Healthcare professionals performing 
lung function tests should be on an appropriate profes-
sional register (where appropriate), for example, Regis-
tration Council for Clinical Physiologists ( www. rccp. co. 
uk), Academy for Healthcare Science ( www. ahcs. ac. uk) 
or Health and Care Professions Council ( www. hcpc- uk. 
co. uk). It has recently been mandated that all opera-
tors performing spirometry in the UK should have the 
equivalent of the ARTP Spirometry Certificate and be 
enrolled on a Register of Spirometry Practitioners,30 
which requires revalidation every 3 years.
Regular feedback of an individual’s performance in 
all aspects of their delivery of a quality assured diag-
nostic service is essential. This is best achieved through a 
planned personal development and review system.
Equally it cannot be presumed that individuals who 
have achieved their qualifications in the past continue to 
be competent without ongoing assessment. The perfor-
mance of practitioners has been shown to decline over 
time.31 Maintaining competency can be achieved via a 
number of means:
 ► Routine quality checks of all results.
 ► Peer review of operators and results.
 ► Interdepartmental comparison of results.18
patient variability
In order to accurately identify changes in lung function 
indices that may be due to a disease process, it is impor-
tant to minimise all variability in the measurements. A 
significant source of variability can be the patient.
Specific factors that are acknowledged to affect partic-
ular tests and the pretest instructions to be given to 
minimise variability have been discussed in the relevant 
sections of this document.
Some local standards will also likely apply to pretest 
instructions, for example whether the clinician inter-
preting the results will want to see baseline spirometry 
performed either prebronchodilator or postbronchodi-
lator. Any known variance from these standard prerequi-
sites needs to be recorded on the test report in the form 
of technical comments.
Overall the contribution that the practitioner makes 
can have a profound effect on the patient’s compliance 
and performance. Clear and precise instructions coupled 
with a firm and confident attitude will induce and 
encourage the best performance from the patient. With 
some reluctant patients it can be important to explain 
the reasons for a test in relation to the clinical context to 
gain cooperation, which is where a good background of 
clinical knowledge and experience is essential.
test variability
Adherence to the principles described in this chapter 
will reduce the potential sources of error in testing 
procedures and ensure consistent and valid results are 
presented.
With good operator technique and good patient coop-
eration, it should be possible to get repeatable readings 
for any subdivision of lung volume that are <150 mL or 
<5%. It has been shown that coefficients of variation of 
<5% for spirometry, <7% for lung volumes and <9% for 
gas transfer are achievable.28
reFerence vAlues
Introduction
Having obtained test results of lung function from a 
subject, a clinician needs to be able to interpret what 
these mean in the context of the patient’s clinical condi-
tion. Any given set of test results may need to be inter-
preted in isolation, and because lung function is related 
to the ethnicity, sex, age and height of the subject we need 
to be able to account for these first before we can decide 
if the subject’s results are in any way unusual. For this 
one relates the result to relevant reference values. (The 
‘Standardised residuals (z- scores)’ section addresses how 
best to assess a subject’s result against their predicted 
value.)
If a clinician is following a patient longitudinally, then 
previously obtained results can be used as a reference to 
help see what is happening to this subject over time. (The 
‘Grading severity’ section addresses some of the issues 
around longitudinal change.)
Sometimes it is necessary to decide how abnormal the 
result is for a subject. This may be to help prognosticate 
from the test result or to decide if a critical level has been 
achieved that triggers a change in management. (The 
‘Grading severity’ section addresses how one can best 
assess the severity of any lung function deficit.)
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Figure 1 Plot of idealised population data for FEV1 in men. 
The left panel shows a plot of FEV1 against age (in years) 
for men of height 1.77 m and on the right a plot against 
height (in metres) for men aged 50 years. Source: Professor 
MR Miller. FEV1, forced expiratory volume in 1 s.
Figure 2 Plot of idealised population data for FEV1: 
standardised residual (SR). FEV1 is plotted against age for 
men of height 1.77 m with a subject’s value O and their 
predicted value P outlined. The sloping line denotes the 
predicted values against age. Thus, FEV1SR=(observed 
FEV1−predicted FEV1)/RSD, where RSD is the residual 
SD taken from the healthy population used to make the 
prediction. Source: Professor MR Miller. FEV1, forced 
expiratory volume in 1 s.
basic principles
The predicted value for a particular lung function 
index is obtained by using reference equations, which 
are discussed later (see ‘Which reference equations?’ 
section). Standardised residuals (SR; also known as 
z- scores) have long been32 and remain5 the preferred 
method for comparing the subject’s recorded value with 
the predicted value. Per cent of predicted is not an accu-
rate method for making a comparison with the reference 
range (see ‘Per cent of predicted’ section). The reasoning 
behind this is explained in the following:
The values for lung function indices within the normal 
healthy population are known to vary according to age, 
sex and height of the subject. So in a large population 
sample there is a scatter of results. Figure 1 shows such a 
scatter for forced expiratory volume in 1 s (FEV1) in men 
against age on the left and against height on the right.
standardised residuals (z-scores)
The scatter of values seen in the young is approximately 
the same as that seen in the elderly. The same is true for 
values with respect to height. For a given age and height 
the results found in a large sample of a healthy population 
approximate to a Gaussian distribution, so it is possible 
to obtain a mean value for a given age and height, and 
the scatter is described by the SD of the distribution. 
The 95% and 90% confidence limits for the normal 
population can then be estimated as mean±1.96×SD and 
mean±1.645×SD, respectively. These values are taken 
from statistical tables and follow the scientific principles 
accepted by all science disciplines worldwide for data 
with normal distributions.
When deriving normal values for tests that are applied 
indiscriminately to the general population (eg, when 
undertaking unselected screening), the 95% confidence 
limits are usually taken, which means the lower limit of 
normal (LLN) is the mean, -1.96×SD, which approx-
imates to the lower 2.5th percentile. Thus 2.5% of a 
healthy population might have a result below this level 
and yet be entirely normal. These would be deemed false 
positives. Because lung function tests are not applied 
indiscriminately in this way but are only undertaken 
when indicated by the presence of symptoms or other 
signs of disease, it is recommended5 to use an LLN of the 
lower fifth percentile (mean −1.645×SD), which trades 
some specificity for increased sensitivity in detecting true 
disease.
Figure 2 shows a patient’s observed result (O) plotted 
in the context of the population results together with the 
subject’s predicted value (P, the mean population value 
for someone of the same age, sex and height). The differ-
ence between O and P is called the subject’s residual. If 
this value is divided by the SD of all the residuals for the 
healthy population, it is called a standardised residual 
(SR).
An SR is a dimensionless number which states how 
many SD the subject’s value is from predicted and this 
is identical to a z- score. A negative SR means the result 
is below predicted. An SR value of 0 means the result is 
identical to the predicted. So an SR of −1.645 puts the 
result on the fifth percentile and is at the LLN.
percent of predicted
In the early 1960s an American textbook on respiratory 
medicine suggested that ‘a useful general rule is that 
a deviation of 20% from the predicted normal value is 
probably significant’.33 This recommendation came with 
no supporting evidence, but the practice has been widely 
applied ever since. Soon after this statement was made, 
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Figure 3 Plot of idealised population data for FEV1: 80% 
predicted and LLN. FEV1 is plotted against age for men of 
height 1.77 m showing a thin line representing 80% of the 
predicted (pred) value and a thick line showing the true 
lower limit of normal (LLN), that is, the fifth centile value 
25–70 years. Source: Professor MR Miller. FEV1, forced 
expiratory volume in 1 s.
Figure 4 Plot of idealised population data for TLC against 
height for men. The thin line represents 80% and 120% of 
the predicted (pred) value, and the thick line shows the true 
lower limit of normal (LLN) and the upper limit of normal 
(ULN), that is, the 5th and 95th centile values. Source: 
Professor MR Miller. TLC, total lung capacity.
a serious flaw in the use of per cent of predicted was 
exposed,34 and this problem was revisited over 20 years 
later.35 The problem is that the natural scatter of lung 
function data within the healthy normal population is 
not proportional to the mean value. This is best seen in 
figure 3, showing that for FEV1 the LLN for older subjects 
is lower than 80% of predicted; this is also seen for forced 
vital capacity (FVC) and carbon monoxide transfer factor 
(TLco).
Figure 4 shows how for total lung capacity (TLC) the 
problem is the opposite way around, with the LLN being 
above 80% of predicted, which is also seen for FEV1/FVC.
Eighty per cent of predicted does not relate predictably 
to the true population LLN for all ages, for all heights 
or for both sexes because the magnitude and scatter of 
results in the healthy population are very different for 
different indices. This is demonstrated in table 3, which 
shows the LLN values for several lung function indices 
for three subjects of differing age, sex and height when 
expressed as per cent of predicted and also shows 80% of 
predicted when expressed as population centiles. It can 
be seen that LLN when expressed as per cent of predicted 
varies widely between subjects and indices.
Because of this variation, if the 20% deviation rule 
is applied to patient lung function data, about 20% of 
subjects will be misclassified in terms of their likely 
disease.33 A clinical diagnostic algorithm using per cent of 
predicted that gets one in five diagnoses wrong is clearly 
not one to recommend, and so per cent of predicted 
should not be used to assess if a patient’s result is unusual.
In table 3, if 80% of predicted equated to LLN, then 
the centile values would all be 5. Centiles above 5 indi-
cate that 80% of predicted is above the LLN.
Forced expiratory volume in 1 s/forced vital capacityFev1/Fvc
The Global Obstructive Lung Disease (GOLD) group in 
200136 introduced the idea of using a fixed value of 0.7 
for FEV1/FVC as the cut- off for defining the presence 
of airflow obstruction. This was based on the results of 
one paper37 that suggested this was the LLN for men, but 
these authors found this was not true for women, where 
the LLN declined with age. The population sampled in 
this paper included very few elderly men, making it unre-
liable. Over 50 other studies worldwide38 have found that 
FEV1/FVC declines with age in both sexes. Using a fixed 
ratio is incorrect practice and overdiagnoses obstruction 
in the elderly (especially men) and underdiagnoses it in 
younger people (especially women).39–41
Using LLN for FEV1/FVC (see ‘Standardised residuals 
(z- scores)’ section) is the correct way to determine the 
presence of airflow obstruction. To illustrate this problem 
figure 5 shows a plot of FEV1/FVC data against age from 
the Health Survey for England data in 200142 for men on 
the left and women on the right. It can be seen that there 
are more false positives in men compared with women 
and more false negatives in women compared with men 
when using the incorrect 0.7 criterion instead of LLN for 
defining airflow limitation.
which reference equations?
A large number of test results are needed from people 
who are free of any disease that may affect lung function 
with an adequate number of men and women and with 
a good range of ages and heights in order to be able to 
make a sensible prediction of what an individual’s lung 
function should be. It has been estimated that at least 
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Table 3 Values for the lower limits of normal
Sex Male Male Female
Age (years) 30 70 70
Height (m) 1.80 1.80 1.55
LLN as % pred
80% pred as 
centile LLN as % pred
80% pred as 
centile LLN as % pred
80% pred as 
centile
FEV1 81 4 74 10 65 18
FVC 81 4 76 8 67 24
FEV1/FVC 86 1 84 2 86 2
PEF 80 5 76 9 72 19
FRC 71 13 74 11 68 20
RV 62 19 75 10 70 17
TLC 84 2 84 2 78 10
RV/TLC 65 17 78 7 78 6
TLco 81 4 75 9 70 18
Kco 75 9 66 17 79 12
Showing the LLN when expressed as per cent of predicted (pred) and 80% of predicted when expressed as population centile for a range of 
lung function indices for three different subjects.
Source: Professor MR Miller.
FEV1, forced expiratory volume in 1 s; FRC, functional residual capacity; FVC, forced vital capacity; Kco, gas transfer coefficient for carbon 
monoxide; LLN, lower limit of normal; PEF, peak expiratory flow; RV, residual volume; TLC, total lung capacity; TLco, carbon monoxide 
transfer factor.
Figure 5 A plot of FEV1/FVC against age. On the left are data for 4991 men and on the right for 5811 women. The horizontal 
line shows the 0.7 cut- off and the slanting line is the LLN. The points above both these lines are within the accepted range for 
both criteria. The points below both lines are abnormal by both criteria. The dark closed circles between the lines to the right 
of each plot are the points positive for airflow limitation by 0.7 but not by LLN (false positives). The open circles between the 
two lines to the left of each plot are abnormal by LLN but not by 0.7 (false negatives). Source: Professor MR Miller from the 
Health Survey for England 2001 data.42 FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LLN, lower limit of 
normal.
150 subjects of each sex are needed in order to make a 
reasonable estimate of what the predicted values should 
be.43 Several data sets used in the past would not meet 
this criterion. The reference subjects should ideally also 
be of similar demographic and ethnic background to 
the people being tested. Clearly reference values taken 
from sampling elite athletes would not be appropriate 
for clinical patients since these athletes usually have 
supranormal lung function, which is why they are able to 
compete successfully in their sport.
Spirometry
In the last few years reference values from the Global 
Lung Initiative (GLI), sponsored by the ERS, have 
become available.44 These have been derived from the 
data of over 70 000 subjects obtained from many nation-
alities so that some aspects of ethnicity can be accounted 
for. This is the largest data set to date for this purpose and 
has used the most sophisticated statistical techniques so 
that one set of equations can be used for subjects from 
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Table 4 Severity grading and probability of a result being 
found within a normal healthy population for various z- score 
thresholds
Threshold for 
z- score Severity grading
Approximate chance 
of finding this result in 
a healthy population
<−1.645 Mild 1 in 20
<−2 Moderate 1 in 40
<−2.5 Moderately severe 1 in 150
<−3 Severe 1 in 750
<−4 Very severe 1 in 30 000
Adapted from Quanjer et al.51
the age of 4 through to 95 years. This latter fact is a great 
advance and these equations should be adopted.
Recent evidence45 suggests that GLI gives too high a 
predicted value for the very elderly (over 90 years old), 
possibly because asymptomatic ‘never- smokers’ of this 
age who are able to participate in providing ‘normal’ lung 
function values are in some sense ‘supra- normal’ for this 
age. Extrapolating National Health and Nutrition Exam-
ination Survey (NHANES) III equations46 was a better 
fit for these subjects. Although it was recommended not 
to extrapolate NHANES III beyond the age of 80 years, 
because at the time of their issue it was not known how 
good such a prediction might be, it now seems that 
extrapolation may well be justified and a better fit than 
the alternative. However the GLI initiative is prospec-
tively collecting healthy controls on the ‘missing’ age and 
ethnic groups, and ARTP recommend the use of GLI 
values in most subjects.
One issue in the past for clinicians managing chil-
dren with lung disease was the previous lack of coherent 
prediction equations that would work through teenage 
years through to early adulthood. The GLI equations 
have addressed this problem. Reference equations for 
children are discussed further in the ‘Paediatric Refer-
ence Values’ section.
Static lung volumes and gas transfer
The European Community for Steel and Coal equa-
tions33 can be used for static lung volume to provide a 
practical set of equations for these indices. The GLI 
group have also developed all- age equations for lung gas 
transfer in Caucasian subjects47 and are collecting data to 
produce reference equations for static lung volumes to 
be published in the near future, and ARTP will be recom-
mending their use when they become available.
For reference equations for children, see the ‘Paedi-
atric Reference Values’ section.
Grading severity
This is often a vital point if it is thought that a particular 
intervention is warranted when a test reaches a certain 
value. Arbitrary cut- off points using per cent of predicted 
values of FEV1 have been suggested to grade severity of 
chronic obstructive pulmonary disease (COPD),36 but 
no objective evidence supported this and per cent of 
predicted values retain age, sex and height bias. A valid 
way to grade severity should relate to subsequent survival, 
and it has been shown that z- scores are not ideal in this 
respect and per cent of predicted is not as good as other 
methods for grading FEV1 values.
48 An important point 
that helps to clarify this is that patients dying of severe 
CF at the age of 20 years have an absolute FEV1 the same 
as a 70- year- old patient dying of COPD, and yet in terms 
of per cent of predicted the value of a patient with CF is 
much lower than that for the elderly patient with COPD. 
This problem led to poor outcomes for transplantation in 
children with CF when a fixed per cent of predicted value 
taken from adult practice was used to trigger transplan-
tation, which was then being undertaken prematurely.49
The z- score thresholds for FEV1 have been proposed 
for assessing the severity of airflow obstruction.50 This 
grading has been adapted in table 4 for the possible 
grading of other indices.
Severity classification in airflow obstruction is a two- 
stage process:
 ► The FEV1/FVC (or FEV1/VC) must be below the LLN 
(z- score <−1.645) to be classified as obstructive.
 ► Severity grading is then based on the FEV1 z- score as 
above, with the exception that the mild classification 
would include any FEV1 z- score ≥−2.
The grading system in table 4 will remove the sex, age 
and height bias implicit in per cent of predicted grading 
systems.50
FEV1 (or FVC) standardised by a power of height has 
been shown to give a better prediction of survival in the 
general population compared with per cent of predicted51 
and gave a better grading of COPD in terms of survival 
than the GOLD grading.52 In UK patients FEV1/ht
3 gave 
a good prediction of survival48; better still at predicting 
survival was the FEV1 quotient (FEV1Q), which is the FEV1 
divided by a sex- specific population first centile value 
(0.5 L in men, 0.4 L in women).41 FEV1Q can be consid-
ered as the number of turnovers of the lower survivable 
limit that remain for the subject. Future work is needed 
to define and compare grading limits from FEV1/ht
3 and 
FEV1Q, which better relate to survival than both per cent 
of predicted values, with their inherent problems (see 
‘Per cent of predicted’ section), and z- scores.
longitudinal trends
Following the progress of a patient during the manage-
ment of their lung disease is the usual clinical scenario, 
and this raises the question of how best to monitor their 
lung function. As this involves a within- subject compar-
ison, it is best to use the absolute values of various lung 
function indices taken together with an understanding 
of how much natural variation there is in each index 
on repeated testing so one can interpret whether an 
observed change is greater than can be expected by 
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chance.53 Estimating true lung function decline can 
require observations over 5–10 years.54
There are many factors that can influence variability 
in lung function. Over time periods of less than 1 year, 
statistical methods of estimating variation are not sensi-
tive. The normal variability over time will also depend 
on the disease process being monitored, for instance as 
described in COPD by Vestbo et al.55
Repeated testing of spirometry can lead to within- 
subject variations of up to 200 mL.53
Since reference equations (see ‘Which reference 
equations?’ section) are all derived from cross- sectional 
studies, z- scores derived from them are not ideal for 
monitoring longitudinal change since this is less on an 
annualised basis than that inferred from cross- sectional 
equations56 due to a cohort effect that has nothing to 
do with longitudinal change. The cohort effect is best 
understood by realising that individuals aged 80 years old 
whose data were included in a set of reference equations 
had different childhood exposures, nutrition and growth 
trajectory than those aged 30 years old included in the 
same data set.
ethnicity
It has long been noted that, for example, the FVC of indi-
viduals of white Caucasians tends to be larger than that 
found in individuals of similar height of African descent. 
This could relate to a poorer socioeconomic background 
during childhood leading to poorer lung development or 
might be a true genetic effect. Current evidence favours 
the latter as the more powerful contributor to this effect.57 
The GLI 2012 equations for spirometry have attempted 
to account for this effect.44 It has to be accepted that this 
is an imperfect fit and there are difficulties in ascribing 
ethnicity to individuals especially those of mixed descent.
summary
It is important when using lung function to make clinical 
decisions to understand the potential problems associ-
ated with these data. Technical issues and patient issues 
may mean the results obtained are not true representa-
tions of the subject’s clinical condition.58
It is important that properly trained healthcare profes-
sionals undertake the tests and have the facility to add 
comments, pointing out if there were any technical issues 
which can be helpful to the clinician interpreting the 
findings.
It is recommended that the report states the z- score 
and normal range to determine whether there is an 
unexpected result for that individual. When determining 
the severity of any unexpected result, the classification as 
outlined in table 4 is currently recommended.
When providing a trend of lung function data over 
multiple visits, the serial display of absolute values is 
recommended.
spIrometry
definitions
Relaxed vital capacity
When the term vital capacity (VC) is used without any 
further qualification, it conventionally refers to relaxed 
vital capacity (RVC). This can be measured in two ways, 
the former being the most common with desktop spirom-
eters. Some spirometers will call this slow vital capacity 
(SVC), but RVC is the preferred term.
Expiratory vital capacity
Expiratory vital capacity (EVC) is the maximum volume 
of gas that can be expired from the lungs during a 
relaxed but complete expiration from a position of full 
inspiration.
Inspiratory vital capacity
Inspiratory vital capacity (IVC) is the maximum volume 
of gas that can be inspired into the lungs during a relaxed 
but complete inspiration from a position of full expira-
tion.
Forced expiratory volume in 1 s
FEV1 is the maximal volume of gas that can be expired 
from the lungs in the first second of a forced expiration 
from a position of full inspiration.
Forced vital capacity
FVC is the maximal volume of gas that can be expired 
from the lungs during a forced and complete expiration 
from a position of full inspiration.
Peak expiratory flow
Peak expiratory flow (PEF) is the maximum flow achiev-
able from a forced expiration starting at a full inspiration 
with an open glottis.
FEFx% (FEF25%, FEF50%, FEF75%)
Forced expiratory flow (FEF) is the maximum flow achiev-
able during a maximum forced expiratory manoeuvre 
when X% of the FVC has been exhaled, that is, FEF25% is 
the maximum flow rate achievable when 25% of the FVC 
has been exhaled and FEF75% is when 75% of the FVC has 
been exhaled.
FEF25%–75%
This is the mean expiratory flow generated between 25% 
and 75% of the FVC during a maximum forced expira-
tory manoeuvre.
equipment calibration/verification
Quality control must be performed on a regular basis to 
determine the accuracy and/or precision of the device 
using a known standard or signal. If barrier filters are 
used, then calibration or verification of the equipment 
must be performed with the filter inserted between the 
calibration syringe and the device.
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Volume calibration
All spirometers should be checked regularly for accu-
racy of volume and linearity. Some devices (eg, wedge 
bellows) cannot be calibrated or internally adjusted to 
read volume accurately each day or session; however, all 
devices can be verified to see whether they read a calibra-
tion signal within acceptable limits.
A 3 L syringe should be used for calibration checks for 
spirometers; the syringe should have an accuracy of 15 mL 
or 0.5%, whichever is greater, and be recommended 
for the calibration of spirometers. These syringes also 
need calibration checks at least annually or if damage is 
suspected (eg, having been dropped).
Calibration checks (verification) should be performed 
at least once for each day of testing and should be 
repeated every 4 hours of use where possible across the 
volume range. If the room temperature changes by more 
than 5°C, recalibration may be indicated. If the device 
is being switched on and off for transportation between 
rooms, then calibration needs to be repeated.
All verification and calibration data should be stored 
either in the machine software or, preferably, in a calibra-
tion log book for the equipment. This is the only guar-
antee of the reliability of the equipment.
Calibration checks should produce a measured value 
within 3% of the syringe volume (ie, between 2.91 L and 
3.09 L for a 3 L syringe). For systems that generate a soft-
ware correction factor, the correction factor should be 
within the range of 0.97–1.03, which is within 3%.
Flow sensing spirometers that measure flow at the 
mouth may require separate correction factors for inspi-
ratory and expiratory volumes. For flow- based spirome-
ters, the 3 L volume should be injected at three different 
flow rates between 2 and 12 L/s; volume accuracy should 
be within 3% at all flows. All calibration syringes should 
be maintained at the same temperature and humidity as 
the spirometer. Calibration syringes should be returned 
to the manufacturer annually for servicing and accuracy 
checking.
Quality control for spirometers should be performed 
as if a subject was being tested and the calibration syringe 
should be connected to the same port as the patient 
would be. Where appropriate, volume verification should 
be performed with an inline bacterial filter.
If the percentage error on calibration exceeds the 
allowable limits, a detailed examination of the spirometer 
and recording device should be performed in order to 
locate the source of any problems. All equipment should 
be checked for damage caused by the equipment being 
dropped. The most common problems that are detected 
are the following:
 ► Cracks or leaks.
 ► Holes in the flow sensor, channel plugging or excess 
moisture (flow sensing devices).
 ► Connectors and tubing with leaks.
 ► Inaccurate timing on the recorder.
 ► Inappropriate or inadequate software calibration, 
or other technical problems with the computer 
interface.
 ► Calibration syringe out of range: the syringe should 
be certified for accuracy at least annually by the 
supplier, as mentioned earlier.
Linearity testing
The linearity of spirometers can be confirmed by intro-
ducing 1 L increments from a calibrated syringe. Some 
suppliers have a 1 L syringe with an inbuilt valve mech-
anism. If using a 3 L syringe, then a two- way non- return 
valve needs to be placed between the syringe and the 
device. By pumping in 1 L increments over the working 
range from 0 to 7 or 8 L, a plot of actual recorded and 
expected volume can be obtained. The process is simple 
and takes no more than 5 min to complete. If the spirom-
eter is indeed linear, the volume recorded for each incre-
ment should match that delivered by the syringe exactly, 
but in reality there may be some small variation between 
the recorded and the expected values.
Testing for leaks
It is important that closed spirometers are checked for 
leaks before a patient is tested on the equipment. The 
spirometer should be filled with air and the end of the 
breathing tube occluded with a rubber bung. The volume 
in the spirometer can be marked on chart paper, and 
then rechecked and recorded after a few minutes have 
elapsed. There should be a difference of less than 50 mL 
between the recorded volumes, otherwise a significant 
leak is indicated.
Physiological control
On a regular basis, a member of staff should undertake 
a forced expiratory and inspiratory manoeuvre to ensure 
that the integrity of the device is fully operational. By 
plotting the data in serial format, which the spirometer 
software may be able to do automatically, variations in the 
key indices can be observed over time.
Initially, in order to understand the variability of a 
subject, a number of technically acceptable measure-
ments need to be made, and their average and variation 
estimated 5%. Thereafter, new values added can be moni-
tored for any possible faults in the system.59
correct performance
The equipment and the subject are prepared for the test 
and the purpose and nature of the test are explained. It 
is useful to demonstrate the technique to the subject to 
enable better understanding of what is required of them. 
Ideally the subject should be sitting upright in a chair 
with arms, their feet flat on the floor. Patients should be 
asked to loosen tight- fitting clothing, where this is obvi-
ously restricting the movement of their chest wall and 
abdomen. Dentures should normally be left in place, 
unless they are loose, in which case it may be advisable 
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to ask them to be removed. A noseclip is not essential 
for the measurement of forced expiratory manoeuvres; 
however, it is required for forced inspiratory manoeuvres 
and for relaxed manoeuvres.60
relaxed vital capacity
Measurements of RVC, sometimes also referred to as SVC, 
should always be recorded prior to a forced manoeuvre, 
because forced manoeuvres may induce bronchospasm/
obstruction. It is best practice to perform an initial meas-
urement of an RVC manoeuvre because relying on FVC 
measurements alone can lead to an underestimation 
of lung volumes in the elderly and those with dynamic 
airway collapse (eg, COPD, emphysema).
RVC can be measured as part of another test (eg, static 
lung volumes) but should always be performed prior to 
any forced manoeuvre.
The subject is initially asked to breathe tidally 
through the mouthpiece, to establish a stable baseline 
at functional residual capacity (FRC). When the oper-
ator perceives that the subject is ready, they should be 
instructed to breathe in maximally and then to exhale 
fully at a sustained and steady flow rate until no further 
gas can be exhaled. It is important that the exhalation 
is continuous, and the subject should be encouraged to 
not hold back but to breathe out initially like a ‘big sigh’ 
followed by a determined effort to maximal exhalation. 
Consistent encouragement should be provided by the 
operator throughout, aiming to achieve a reproducibility 
of <150 mL between measurements.
Where specific equipment does not allow tidal 
breathing prior to the manoeuvre, it is essential that 
the operator observes and encourages the subject to 
ensure a maximal inhalation prior to attaching to the 
mouthpiece and that a tight seal is achieved quickly to 
prevent any effect on the measured exhalation.
maximal flow-volume loop
For the accurate determination of forced expiratory 
indices, it is essential that the subject takes a maximal 
inhalation at the start of this manoeuvre, ensures that the 
exhalation is not delayed and is ‘blasted’ from the lungs 
as fast as they can, and that exhalation continues until no 
further gas can be exhaled.
The subject is again asked to breathe tidally through 
the mouthpiece to start. Once they are comfortable 
they are asked to take a maximal breath in and to exhale 
immediately ‘as hard and as fast as they can’. The exha-
lation should be encouraged throughout until the 
end of forced expiration criteria (see ‘End of forced 
expiration’ section) are achieved or the patient termi-
nates the test. There should be minimal pause between 
achieving maximal inhalation and commencing exhala-
tion (<1 s) as longer delays have been shown to impact 
on measured values of FEV1 and PEF.
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Once maximal exhalation is achieved, the subject 
should be encouraged to immediately breathe back in, 
forcefully and maximally, to full inspiration.
Where specific equipment does not allow tidal 
breathing prior to the manoeuvre, it is essential that 
the operator observes and encourages the subject to 
ensure a maximal inhalation prior to attaching to the 
mouthpiece and that a tight seal is achieved quickly to 
prevent any effect on the measured exhalation.
The subject should be carefully observed throughout 
testing to ensure they maintain the appropriate effort 
throughout the duration of the blow and that they do 
not cough or hesitate at the start of the blow.
A minimum of 30 s should be left between repeat 
attempts to allow the patient, particularly those with 
airflow obstruction, to recover. Patients should not be 
made to attempt repeat manoeuvres before recovery is 
complete.
Acceptability criteria
The objective is to obtain the best result for the subject 
on the day of the test. Various aspects of the manoeuvre 
need to be considered in order to be sure the subject has 
achieved the very best result.
Failing to satisfy all these aspects does not necessarily 
invalidate the results completely but will mean that they 
will be a less reliable estimate of their true lung function. 
Rather than deleting all the data from unsatisfactory 
tests, it is better to retain these and then base the final 
results on the best tests obtained. A single unsatisfactory 
test result may still be able to answer a clinical question, 
for example whether the subject has sufficient function 
to be able to undergo a surgical procedure. If results are 
derived from tests that are in some aspects unsatisfactory, 
then the operator must draw attention to this fact in their 
technical comments.
Throughout test performance the subject should 
be observed to ensure that they are carrying out the 
instructions correctly, do not exhale prematurely or lose 
expired gas around the mouthpiece. These and other 
examples of incorrect performance can be observed 
on the flow- volume loop (figure 6) The subject must 
be encouraged to ensure that they continue to exhale 
until the flow of gas has ceased. In patients with airflow 
obstruction exhalation, either forced or relaxed, can 
be in excess of 10 s. A test will be suboptimal in the 
following circumstances:
 ► The patient did not inspire to TLC at the start*.
 ► A leak at the mouth.
 ► An obstructed mouthpiece due to tongue or false 
teeth.
 ► A poorly coordinated start to the manoeuvre, as indi-
cated by a rise time of 10%–90% of PEF of greater 
than 150 ms, or a back- extrapolated volume of greater 
than 5% of the FVC or 0.1 L if the FVC is less than 
2.0 L.3
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Figure 6 Examples of spirometry errors. The blue line is the ideal curve and the red line(s) the erroneous curves. Source: 
ARTP Spirometry Handbook.
 ► A cough within the first one second of the manoeuvre 
or later if it is deemed to have interfered with the 
blow.
 ► Early termination of the blow or a Valsalva 
manoeuvre**.
 ► The test was conducted with a submaximal effort.
*If the maximum forced expiratory manoeuvre is 
followed immediately by a full inspiration back to TLC 
and recorded as a single manoeuvre, then the Forced 
Inspiratory Vital Capacity (FIVC) must not exceed the 
FVC by more than 100 mL or 5% of FVC, whichever is the 
greater. If FIVC exceeds FVC by more than this, then it 
suggests the blow was not started from TLC. Correct cali-
bration of the recording device to account for the differ-
ences (temperature and content) between expired and 
inspired air is crucial for this determination.
**Early termination of a test is not a reason to elim-
inate all data obtained from the manoeuvre as indices 
such as FEV1 may not have been influenced and will still 
be valid.
A graphical display of the expiratory manoeuvre is 
essential to allow the operator to inspect the trace for 
accuracy. The correct aspect ratio for the graphical plot 
of a flow volume loop (flow versus volume) is two units of 
flow per one unit of volume.3
end of forced expiration
The end of forced expiration occurs when the subject 
can blow out no more air and defines the VC. Premature 
termination of the blow will lead to an underestimate of 
the FVC and will falsely increase the FEV1/FVC ratio.
One of the indicators of the end of a forced expira-
tion is a plateau on the spirogram with less than 0.025 L 
being expired over the last 1 s of the test. However, some 
subjects with severe airflow obstruction never achieve 
such a plateau even after exhaling for 20 s. Previously it 
has been suggested the blow should be maintained for 
at least 6 s in adults, but younger subjects may complete 
the manoeuvre in less time than this, as do patients with 
a severe restrictive defect. The operator should always 
encourage the subject to blow out for as long as possible. 
Failure to obtain a plateau and/or 6 s of exhalation is not 
ground to reject the blow. Exhalation times of >15 s are 
unlikely to change clinical decisions.3
repeatability criteria
Subjects must perform a minimum of three technically 
acceptable maximum forced expiratory manoeuvres. 
The performance of at least three blows ensures a greater 
probability of obtaining an accurate result.
The chosen values for FVC and FEV1 should not differ 
from the next best values for FVC and FEV1 by more than 
150 mL. In subjects with a FVC of <1.00 L, this difference 
should not be greater than 100 mL.
If the repeatability criteria are not achieved, then the 
manoeuvre can be repeated up to eight times, after which 
the probability of getting a better result is greatly reduced. 
If after all manoeuvres have been performed the above 
repeatability criteria have not been achieved, the results 
must not be rejected. The operator should label the 
results as not being repeatable allowing the interpreter 
to use the data accordingly. Poor repeatability means that 
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the subject’s results are not a reliable estimate of their 
best function, so a further test may yield a different result 
due to the inherent variability in the subject.
For PEF about 90% of subjects can achieve three 
measures within 30 L/min (0.5 L/s)62 and 95% are within 
40 L/min (0.67 L/s). Persisting beyond five attempts to 
achieve a repeatable PEF is not likely to improve the 
repeatability.3 The highest reading of at least three 
acceptable blows should be recorded. These should be 
within 40 L/min of each other.63
selection of test results
The results chosen should be the greatest values from 
three technically acceptable tests (the FVC and FEV1 
may therefore be taken from different manoeuvres and 
FEV1/FVC calculated from these). Some electronic 
equipment automatically selects the best test, based on 
the individual manoeuvre, which gives the highest figure 
when FEV1 and FVC are added together. This practice is 
not recommended.
If three technically acceptable and/or reproducible 
results are not achieved, the reason should be given in 
the report (eg, patient coughing or too unwell to perform 
the manoeuvre).
Results from recordings that do not meet all the above 
criteria for acceptability may still be useable with clinical 
discretion.
potential problems
Many devices for recording spirometry now use flow as 
the primary measure rather than volume. Many devices 
(eg, pneumotachographs, ultrasonic flow heads) need to 
register the signal that represents zero flow prior to a test. 
If this is registered incorrectly then all subsequent flow 
measurements are incorrect. These are termed ‘zero flow 
registration errors’.
If volume accumulating spirometers are used (rolling- 
seal or wedge bellows), then cooling errors can occur since 
the gas at the moment of registering the exhaled volume 
is above ambient and subsequently cools. When a BTPS 
correction is made to FEV1 and FVC using the ambient 
temperature, this assumes that the gas had reached 
ambient at the time the index value was recorded. This is 
untrue for FEV1 and also untrue for FVC if it is registered 
within just a few seconds. These cooling errors tend to 
lead to FEV1 being falsely high relative to FVC. Heating 
the volume accumulating spirometer to 33°C will remove 
these errors as this approximates to the expired gas 
temperature at the lips.
bronchodIlAtor response
rationale
The reasons for delivering a bronchodilator drug in 
the context of lung function testing may include the 
following:
 ► To see if useful improvement in lung function can be 
achieved.
 ► To record lung function post bronchodilator to see if 
airflow obstruction is still present.
 ► To help confirm the presence of asthma.
It has been argued that asking the patient whether any 
useful improvement is achieved may be a better indicator 
than any particular test for assessing ‘useful improve-
ment’. However an improvement in FEV1 by >4% of the 
subject’s predicted value has been found to be associated 
with useful improvement as assessed both by the subject 
and their peers.64
Recording postbronchodilator spirometry has been 
recommended for determining if someone has COPD. 
The idea being that any ‘reversible’ component will 
then have been relieved and it would be reasonable to 
presume that any remaining obstruction would be ‘fixed’. 
However bronchodilator response may be variable day to 
day so this is not entirely true.
There is debate about what degree of responsiveness 
would indicate the presence of asthma to distinguish it 
from other respiratory diseases. The result from short- 
term bronchodilator responsiveness alone is not a reli-
able method for making a diagnosis of asthma, as this 
clinical diagnosis is based on clinical examination and 
history together with diagnostic tests.63
methods
Depending on the purpose of the test, other broncho-
dilator drugs that the patient is taking may need to be 
stopped for an appropriate time prior to testing (see 
‘Withholding bronchodilators’ section) so that the 
response to the bronchodilator being assessed can be 
determined.
Maximal forced expiratory manoeuvres are undertaken 
(as described in ‘Spirometry’ section) to record FEV1, 
FVC, RVC and PEF preadministration and postadminis-
tration of a bronchodilator. The drug used may be salbu-
tamol or terbutaline for a β2 agonist and/or ipratropium 
bromide for an anticholinergic agent. Delivery may best 
be undertaken by supervising the use of a metered dose 
inhaler with a spacer device, but a nebuliser could be used 
alternatively. An appropriate delay after administration 
must occur to allow the drug to achieve maximum effect 
(15 min for a β2 agonist and 30 min for an anticholinergic 
agent).3 Administration and dose of any prescribed medi-
cation should be covered by local protocol.
expressing the results
The absolute changes in FEV1, FVC and PEF are to be 
recorded. There have been many suggested thresh-
olds for determining if a clinically important degree of 
responsiveness has occurred,65 and all those based on 
percentage of baseline value and/or absolute change 
from baseline can lead to bias.
Previous practice has been to express the change as a 
per cent of the baseline value, but this leads to sex and 
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box 1 Different methods for calculating bronchodilator 
response
 ► Absolute change (mL) from prebronchodilator value.
 Postbronchodilator FEV1 − Prebronchodilator FEV1(mL) 
 ► Percentage of initial prebronchodilator value (% initial).
(Post BD FEV1−Pre BD FEV1)×100
Pre BD FEV1
 ► Percentage of possible reversibility (% possible).
(Post BD FEV1−Pre BD FEV1)×100
Predicted FEV1−Post BD FEV1
 ► ECCS recommendation.
(Post BD FEV1−Pre BD FEV1)×100∑
(Pre BD FEV1−Post BD FEV1)/2
 ► Percentage of predicted (% predicted).
(Post BD FEV1−Pre BD FEV1)×100
Predicted FEV1
 ► Δz- score.
∆ FEV1 = Post, zFEV1 − Baseline, zFEV1
 ∆ FEV = Post, zFEV− Baseline, zFEV  
BD, bronchodilator; ECCS, European Community for Coal and Steel; FEV1, forced 
expiratory volume in 1 s; RD, residual volume.
size bias in the results, since the lower the baseline value 
the easier it is to achieve a given threshold percentage 
change. Also an absolute threshold criterion is often 
added and this biases results towards male sex being 
responders. It has been proposed that change should be 
expressed as per cent of the subject’s predicted value32 65 
or as change in z- score66 as these methods are free from 
sex and size bias (box 1).
A change in FEV1 of >8% of predicted has been shown 
to be associated with a subsequent survival advantage 
that would favour a diagnosis of asthma and active treat-
ment.65 A change in z- score of 0.7 has also been proposed 
as a clinically meaningful change,66 and the authors also 
found that improvement of FVC postbronchodilator of 
>0.64 was more pronounced in those with the most severe 
airflow obstruction, suggesting a clinically important 
relief of hyperinflation.
Ideally bronchodilator response should be expressed 
as Δz- score for both FEV1 and FVC, with the %predicted 
response being an acceptable alternative.
stAtIc lunG volumes: IntroductIon
Residual volume (RV), FRC and TLC cannot be meas-
ured directly. There are several accepted methods for 
determining these volumes, and the related indices, 
which are frequently referred to as ‘static lung volumes’. 
These methods include whole body plethysmography, 
nitrogen washout and helium dilution. Whole body 
plethysmography is recognised as a ‘gold standard’ 
method for the measurement of static lung volumes.67
In individuals with normal lung function, there should 
be minimal difference between FRC measured by whole 
body plethysmography (FRCPLETH) and gas washout/
dilution techniques. However in patients with obstruc-
tive pulmonary disease with gas trapping, most studies 
indicate that FRCPLETH exceeds the FRC measured by gas 
washout/dilution68 69 and may do so to a considerable 
degree as this technique includes an estimation of unven-
tilated parts of the lungs (‘trapped’ gas).
definitions
Total lung capacity
TLC is the volume of gas in the lungs and airways at the 
position of full (maximal) inspiration.
Vital capacity
When the term vital capacity is used without any further 
qualification, it conventionally refers to an RVC measure-
ment (sometimes also referred to as SVC), which can be 
measured in two ways:
 ► EVC: the maximal volume of gas which can be expired 
from the lungs during a relaxed expiration from a 
position of full inspiration.
 ► IVC: the maximal volume of gas which can be inspired 
into the lungs during a relaxed inspiration from a 
position of full expiration.
Residual volume
RV is the volume of gas in the lungs and airways at the 
position of full expiration.
Tidal volume
Tidal volume is the volume of gas expired or inspired 
during one breathing cycle.
Functional residual capacity
FRC is the volume of gas in the lungs and airways at the 
end of a tidal expiration.
Expiratory reserve volume
Expiratory reserve volume (ERV) is the volume of gas 
which can be maximally expired from the position of 
FRC.
Inspiratory capacity
Inspiratory capacity (IC) is the maximum volume of gas 
which can be inspired from the position of FRC.
Inspiratory reserve volume
Inspiratory reserve volume is the maximum volume 
of gas which can be inspired from the position of end- 
inspiratory tidal volume.
Lung volumes should be expressed in litres at BTPS.
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Figure 7 Static lung volumes shown on a volume versus time spirogram. The blue line is the ideal curve and the red line(s) 
the erroneous curves. Source: ARTP Spirometry Handbook. BTPS, body temperature and pressure saturated.
calculation of the lung volume subdivisions
Using the directly measurable values obtained from a 
spirometry manoeuvre and the indirectly measured lung 
volumes estimated by one of the techniques discussed in 
the following sections, the lung subdivisions can then be 
derived (figure 7):
TLC can be calculated as either TLC=RV+VC or 
TLC=FRC+IC.
RV is either RV=FRC–ERV or TLC–VC.
The former equation is preferable and ideally should 
be calculated from measurements performed without 
the patient disconnecting from the mouthpiece as the RV 
can be miscalculated in patients with significant obstruc-
tion when using the VC from a separate spirometric 
measurement.4
specific to whole body plethysmography
Thoracic gas volume
Thoracic gas volume (TGV) is the volume of compress-
ible gas within the thorax at the time of airflow occlusion 
during plethysmographic measurement, which may be 
higher or lower than FRC depending on precisely where 
airflow occlusion occurs during the tidal breathing cycle.
FRC determined by whole body plethysmography
This is the volume of intrathoracic gas measured when 
airflow occlusion occurs at FRC. A correction may be 
applied to TGV to obtain FRCPLETH.
Alveolar dry gas pressure
Alveolar dry gas pressure (PALV) is the pressure in the 
alveoli at any point throughout the respiratory cycle. 
ΔPALV is the change in alveolar pressure. When the glottis 
is open with no airflow, PALV is the difference between 
ambient PBOX and saturated water vapour pressure at 
body temperature (PH2O,sat).
Mouth pressure
Mouth pressure (PMOUTH) is the airway pressure measured 
at the mouth at any point throughout the respiratory 
cycle. ΔPMOUTH is the change in pressure measured at the 
mouth during panting against a closed shutter.
Box pressure
Box pressure (PBOX) is the pressure measured within the 
sealed body box at any point throughout the respiratory 
cycle. ΔPBOX is the change in pressure measured within 
the body box.
Shift volume
Shift volume (ΔV) is the change in TGV as determined 
from the change in plethysmographic gas pressure 
during compression and decompression of thoracic gas, 
expressed as a volume.
Flow
Flow (V̇) is measured at the mouth or via a transmural 
port which when integrated electronically or mathemati-
cally yields volume.
meAsurement oF lunG volumes: whole body 
plethysmoGrAphy
measurement principles
This section relates to constant volume plethysmog-
raphy.70 The principle of whole body plethysmography 
is based on Boyle’s law, which states that at a constant 
temperature, the volume (V) of a given mass of an ideal 
gas is inversely proportional to its pressure (P), that is, 
PV=K. The constant (K) is proportional to the mass of 
the gas (the number of moles) and its absolute temper-
ature. Assuming that temperature remains constant 
(isothermal conditions of measurement), the following 
mathematical expression is developed:
P1 × V1=P2 × V2
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Figure 8 Body plethysmographic method for lung volume estimation. Body plethysmograph (body box) for measuring 
thoracic gas volume (VL). The subject (in B) relaxes at end–expiration (~FRC) with PMOUTH=PALV=PBOX=Patmospheric (Pb). 
The shutter (see A) is closed in C, and the subject pants slowly and gently; on inspiration VL is rarefied and increases by 
ºΔV, PMOUTH falls and PBOX rises (box gas is compressed by + ΔV lung). ΔPBOX is plotted against ΔPMOUTH . Subsequently, the 
shutter opens and inspiratory capacity is measured using the pneumotachograph signal (see A). Note calibrating signal for 
assessing ΔPBOX in terms of ΔVbox. Reproduced from Hughes, ‘Physiology and Practice of Pulmonary Function’ published 
by the Association for Respiratory Technology & Physiology. FRC, functional residual capacity; PALV, alveolar pressure; PBOX, 
barometric pressure; PMOUTH, mouth pressure.
Determination of TGV is possible if the lungs can be 
treated as a closed compartment and if alveolar pres-
sure can be measured simultaneously to the changes in 
volume. At the end of a tidal expiration, with the airway 
open (ie, at FRC), PALV closely approximates PMOUTH, 
which is equal to atmospheric pressure. The lungs are 
made a closed compartment by closing a shutter at the 
mouth at the end of a tidal expiration. This prevents 
airflow. The patient is instructed to make gentle panting 
efforts with the shutter closed. This causes rarefaction of 
the gas in the lungs during inspiratory efforts (TGV↑, 
PALV↓) and compression of the gas in the lungs during 
expiratory efforts (TGV↓, PALV↑).
TGV=PMOUTH × ΔV/ΔP
As the panting manoeuvre commences at the end of 
a tidal expiration where PMOUTH is equal to atmospheric 
pressure (PB) the equation can be simplified to the 
following:
TGV=PB × ΔV/ΔP
ΔV/ΔP represents the slope of the simultaneous 
changes in box volume versus the changes in PMOUTH.
The measured TGV includes equipment dead space 
(which is known and documented by the manufac-
turer) as well as any volume inspired above resting end- 
expiratory lung volume at the moment of occlusion. 
FRCPLETH is derived from TGV by subtraction of these two 
components of volume (figure 8).
Assumptions of plethysmography
During plethysmographic measurements the airway 
opening is briefly occluded to hold the lung at a constant 
volume (normally at end expiration, ie, FRC). Respira-
tory efforts that compress and rarefy the thoracic volume 
are recorded. By relating changes in PALV (reflected by 
pressure changes at the airway opening during periods 
of no airflow) to changes in thoracic gas alveolar volume 
(reciprocal to pressure changes in the plethysmograph), 
TGV at the moment of the occlusion can be calculated. 
There are however a number of assumptions relating to 
this technique.
Pressure-volume changes in the body are isothermal
An underlying assumption of the technique is that the 
pressure- volume changes in the body are isothermal. 
During inspiration, air is warmed and humidified to 
body temperature and pressure under saturated condi-
tions (BTPS), and air is cooled during expiration. It is 
assumed that any heat generated by warm, expired air is 
instantaneously lost to the surrounding tissue, such that 
changes of alveolar volume will occur under isothermal 
conditions. However, during rarefaction and compression 
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of gas within the plethysmograph, heat may or may not 
be lost through the walls of the container (ie, conditions 
within the plethysmograph are not isothermal). The 
plethysmograph must therefore be calibrated at an appro-
priate frequency to mimic respiratory efforts. The plethys-
mograph is also open to the atmosphere via a small leak 
with a mechanical time constant of between 5 and 25 s. 
This controlled leak minimises slowly occurring pressure 
changes that are not related to respiratory manoeuvres, 
such as thermal drift (heating) caused by the presence of a 
subject breathing and body heat within a closed chamber.
Linear behaviour between changes in PMOUTH and PALV
The respiratory system comprises both elastic recoil 
forces and resistance forces; thus, a pressure change in 
the respiratory system will take a finite time to come to 
equilibrium. This time constant (τ) of the respiratory 
system is a function of the elastance/compliance and 
resistance of the system and is the time taken for 63% of 
a step change to stabilise.
Defined as τ=1/elastance × resistance; or τ=compliance 
× resistance.
Stiff lungs (low compliance) with a low resistance 
will therefore have a short τ and empty and fill rapidly, 
whereas lungs with normal/high compliance and high 
airways resistance will have a long τ and will empty/
fill more slowly. The main assumption of body plethys-
mography is that changes in PMOUTH closely approximate 
changes in PALV during respiratory efforts against an 
occlusion (ie, there is equilibration); however, in airflow 
obstruction (where there is a long τ) the PMOUTH and PALV 
may not have time to equilibrate; hence, the change in 
PMOUTH may potentially underestimate the changes in PALV 
in the presence of airways obstruction and overestimate 
total TGV.
Pressure-volume changes are limited to the volume of gas within 
the thorax
Another assumption of body plethysmography is that 
changes in body volume during respiratory efforts against 
the occlusion are essentially only those of TGV and that 
abdominal gas is negligible. Guidelines therefore recom-
mend avoiding consumption of fizzy drinks prior to 
plethysmographic measurements, since increased abdom-
inal gas and/or pressure swings could be a potential source 
of error.71 Significantly, plethysmographic FRC measures 
all the volume in the lungs at the end of expiration (TGV) 
including any gas trapped behind closed airways. This 
contrasts with gas washout or dilution techniques (eg, 
nitrogen washout), which rely on gas mixing and only 
measure communicating ventilated areas of the lungs and 
not gas trapped in poorly or non- ventilated areas.
Pressure changes applied to the lung are homogeneous within the 
pleural space
Finally, the principles of body plethysmography are 
based on the assumption that pressure changes applied 
to the lung are homogeneous within the pleural space. 
The significant chest distortion observed in some infants 
with respiratory disease may be associated with inhomo-
geneous pleural pressure swings during airway occlu-
sion. Similarly, in the presence of marked ventilation 
inhomogeneity, ∆PMOUTH may not reflect mean changes 
in PALV, potentially resulting in either overestimation or 
underestimation of FRC especially in severe small airways 
obstruction.
equipment calibration/verification
Volume, flow and pressure measuring devices within the 
body plethysmograph should be calibrated daily or more 
frequently when atmospheric conditions are change-
able. The leak time constant should be checked daily 
according to manufacturer recommendations.
subject considerations
There may be reasons that a subject will be unable to 
perform body plethysmography and these could include 
the following:
 ► Conditions that prevent the subject from entering the 
plethysmograph cabinet or adequately performing 
the required manoeuvres.72
 ► Claustrophobia that may be aggravated by entering 
the plethysmograph cabinet.72
 ► Presence of devices or other conditions, such as 
continuous intravenous infusions with pumps or 
other equipment that will not fit into the plethysmo-
graph, that should not be discontinued, or that might 
interfere with pressure changes (eg, chest tube, tran-
stracheal O2 catheter or ruptured eardrum).
72
 ► Continuous oxygen therapy that should not be 
temporarily discontinued.72
test performance
The equipment and the subject are prepared for the 
test figure 9 and the purpose and nature of the test are 
explained. It is useful to demonstrate the technique to 
the subject to enable better understanding of what is 
required of them.
A noseclip is required for the measurement. Dentures 
should remain in place as removal may introduce leaks 
at the mouthpiece. Ideally the subject should be sitting 
upright with their head in the neutral position while in 
the plethysmograph. The box door is closed and suffi-
cient time is allowed for thermal equilibration prior to 
commencement of the test (the appropriate time for 
equilibration will depend on the particular box being 
used). A flange- type mouthpiece helps to prevent leaks 
during the measurements.
For lung volume measurement the subject should be 
requested to breathe normally on the mouthpiece. If 
there is excessive ‘looping’ of the trace, the flat of the 
hands can be placed against the cheeks to reduce their 
movement while the shutter is closed. However, raising 
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Figure 9 Effect of incorrect panting technique on plethysmograph trace. (A) Gentle, properly performed panting manoeuvre 
yielding a series of almost superimposed straight lines. (B) Panting with excessive force leading to hysteresis. (C) Grossly 
excessive panting manoeuvre yielding large, variable, invalid recording. (D) Demonstrates the effects of a leaking box seal.
Figure 10 Volume correction must be applied to TGV 
to determine FRCPLETH. FRC, functional residual capacity 
measured by whole body plethysmography; TGV, thoracic 
gas volume.
the arms can lead to an alteration of FRC so time should 
be allowed for the FRC to adjust before proceeding. Prior 
to initiating the TGV manoeuvre, ensure there are no 
drift or leaks on the tidal volume trace.
The shutter is then closed at the end of a normal 
tidal expiration and the subject is asked to pant gently 
against the shutter at a frequency of approximately one 
breath per second. The shutter should remain closed 
for approximately 2–3 s to obtain 2–3 slopes of ΔPMOUTH 
versus ΔPBOX. Panting frequencies of >1.5 Hz may lead to 
errors and those <0.5 Hz may cause problems with the 
controlled leak of the body plethysmograph system; also 
panting pressures should not exceed ±1 kPa.4 A series 
of almost superimposed straight lines separated by only 
a small thermal drift on the ΔPMOUTH versus ΔPBOX plot 
should be seen. Without removing the mouthpiece the 
subject then performs an RVC manoeuvre immediately 
after the shutter is reopened. Some equipment allows 
these manoeuvres to be recorded prior to the shutter 
being closed.
This whole procedure should be repeated until a 
minimum of three technically acceptable measurements 
have been obtained. The subject may be permitted to 
remove the mouthpiece and take a short pause between 
measurements.
It is important that each ΔPMOUTH versus ΔPBOX trace 
is inspected and the line of best fit adjusted manually if 
necessary.
The measured TGV is the volume of intrathoracic gas 
at the time the airway was occluded. If this was not at the 
true FRC (figure 10), then an appropriate adjustment 
should be made to obtain the correct FRC (FRCPLETH).
repeatability criteria
At least three FRCPLETH values that are technically accept-
able and agree within 5% (ie, the difference between the 
highest and lowest values divided by the mean is ≤5%) 
should be obtained and the mean value reported. If there 
is a larger deviation, additional values should be obtained 
until three values agree within 5% of their mean, and the 
mean value should be reported.
Quality control
Standard quality control procedures should be suffi-
cient (biological control, volume/flow/pressure calibra-
tions and leak check). However, if more detailed quality 
control procedures (eg, for research) are required, then 
a lung volume isothermal simulator, often referred to as 
an isothermal flask, can be used.68 73
meAsurement oF lunG volumes: nItroGen wAshout
measurement principles
At end- tidal expiration the volume of gas in the lungs 
(FRC) is unknown. It is known that this gas contains 
approximately 79% nitrogen; by measuring this volume 
of nitrogen, the FRC can be estimated. In this method 
the subject breathes 100% oxygen, which washes out the 
nitrogen from the lungs, and the total volume of nitrogen 
exhaled is measured (figure 11).
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Figure 11 Calculation of functional residual capacity (FRC): breath by breath method.
equipment
The components of a system comprise a flow trans-
ducer (heated wire flow sensor, ultrasonic flow sensor 
or pneumotachograph), an oxygen supply delivered 
via a demand valve or a flow bypass/reservoir system, a 
method of nitrogen analysis and a mouthpiece assembly 
with valve control.
Commercial systems provide automatic control of 
the equipment and incorporate calibration and quality 
control software to ensure the accuracy of lung volume 
measurements.
equipment calibration/verification
The calibration of the gas analysers and flow transducer 
should be checked daily using certified gases and a cali-
bration syringe. A record should be kept highlighting any 
trends in drift. Gas analysers should also be checked for 
linearity on a quarterly basis (if the system allows). FRC 
calibration should be verified daily by using a syringe 
of known volume (typically 2–3 L). A weekly biological 
control check should also be made by measuring the 
FRC in a normal control subject (see ‘Quality assurance’ 
section).
If using a filter, it is important to deduct the volume of 
the filter from the FRC measurement. This facility is built 
into the software of most commercial systems.
subject considerations
 ► System leaks may occur if the patient has a perforated 
eardrum (if the Eustachian tube is patent, atmos-
pheric nitrogen could enter the system).
 ► Subjects should not be tested if their supplemental 
oxygen therapy cannot be discontinued for a period 
that would allow the air in their lungs to return to 
ambient conditions.
 ► Breathing 100% oxygen can be dangerous in patients 
who retain CO2. Since most patients tend to increase 
tidal breathing while attached to lung function equip-
ment, CO2 retention is not normally a problem. It is 
important that the equipment provides a continuous 
reading of end- tidal CO2 throughout the test to check 
it does not increase.
 ► Patients who are receiving bleomycin are at risk of 
developing pulmonary toxicity when breathing high 
concentrations of oxygen. For this reason, it is advised 
that lung volumes should not be measured using the 
nitrogen washout test.74
 ► It is important to note that other tests which may be 
influenced by oxygen breathing (eg, transfer factor, 
blood gases and so on) should not be performed 
immediately after measuring FRC. To allow the 
partial pressure of oxygen (PO2) to return to baseline 
before proceeding with a further test, at least twice 
the previous washout duration must have elapsed.75 76
test performance
As with all lung volume measurements, a flange- type 
mouthpiece should be used for this procedure to prevent 
leaks during the course of the measurement.
The purpose and nature of the test are explained. The 
height of the mouthpiece should be adjusted so that the 
patient is sitting upright. Both feet should be positioned 
on the floor directly in front of the seat. The patient 
should not be able to view the recording during the 
course of the test as this may influence their breathing 
pattern. The patient is connected to the mouthpiece 
with noseclip attached. Once a stable breathing pattern 
is obtained, the subject is switched into breathing 100% 
oxygen at the end of a normal tidal expiration.
The subject continues with tidal breathing on 100% 
oxygen until the concentration of expired nitrogen falls 
below 1.5% for three consecutive breaths. If this is not 
achieved within 10 min the test should be terminated 
and a note made of the final FRC reading, the remaining 
expired nitrogen concentration and that the end of test 
criterion was not satisfied.
The time taken for the nitrogen washout test will vary 
depending on the degree of airflow obstruction present. 
The duration of the test will be very similar to the helium 
dilution method.
Once the FRC measurement is complete, a minimum 
of three acceptable VC measurements should be made 
by asking the patient to perform a relaxed exhalation 
to RV, followed by a maximal inspiration to TLC. This 
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Figure 12 (Left) Normal washout profile. (Right) Abnormal washout profile typical of emphysema.
Figure 13 Nitrogen washout profile demonstrating a leak.
is the preferred method in patients with airflow obstruc-
tion where marked differences in VC may be observed 
between IVC and EVC manoeuvres. At least 30 s rest 
should be allowed between measurements, and repeat-
ability between the best two VC measurements should be 
within 150 mL (figure 12).77 78
The time taken for the nitrogen washout test will vary 
depending on the degree of airflow obstruction present. 
The duration of the test will be very similar to the helium 
dilution method.
repeatability criteria
Traditionally one technically acceptable result has been 
reported; however, there is little published evidence to 
support this as best practice and caution should therefore 
be used in the interpretation of a single FRC N2 meas-
urement.4 ERS/ATS guidelines recommend performing 
three measurements.76 The time between measurements 
must be at least twice the length of time of the previous 
test to allow alveolar gas concentrations to return to 
normal. Repeatability between technically acceptable 
measurements should be within 10% and the average 
value quoted.
Quality control
It is important that a true FRC is measured, so care must 
be taken to ensure the switch to breathing 100% oxygen 
occurs at the end of a tidal breath during a period of 
stable tidal breathing. Most computerised systems will 
automatically adjust the FRC for small switch- in errors of 
less than 500 mL.
As the exhaled nitrogen is being analysed at the mouth-
piece on a breath- by- breath basis, the exhaled nitrogen 
profile will instantly display a spike should any leak occur 
at the mouthpiece or via the nose (figure 13). The test 
should then be discontinued and not repeated until twice 
the duration of the failed test has elapsed. System leaks 
occur most frequently as a consequence of the lips not 
being tightly sealed around the mouthpiece or a poorly 
fitting noseclip.
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Figure 14 Calculation of FRC: helium (He) dilution method. Closed circuit for He equilibration and calculation of thoracic gas 
volume and FRCHe. System volume includes spirometer and all tubing and so on, up to the valve in the mouth, and is filled 
initially with 10% He. Because of CO2 absorption and O2 consumption, spirometric trace has rising baseline, made horizontal 
by continuous O2 addition. Time course of He equilibration and in normal and in patient with chronic obstructive pulmonary 
disease (COPD) shown. Reproduced from Hughes, ‘Physiology and Practice of Pulmonary Function’, published by the 
Association for Respiratory Technology & Physiology. FRC, functional residual capacity; IC, inspiratory capacity; TLC, total 
lung capacity.
meAsurement oF lunG volumes: helIum dIlutIon
measurement principle
Multiple breath gas dilution measurements of static lung 
volumes are based on the principle that helium (being 
used as a physiologically inert tracer gas) of known 
concentration contained in a spirometer of known 
volume will be diluted by alveolar gas when the subject is 
switched into the system and a closed spirometer circuit 
is maintained (figure 14). A circulating pump within the 
spirometer maintains an even distribution of the test 
gases and the volume of the circuit is kept constant by 
absorbing the CO2 that the subject produces during the 
measurements and replenishing the O2 taken up. After 
a few minutes of tidal breathing, the tracer gas should 
be evenly distributed throughout the subject’s lungs, and 
a second, lower tracer gas concentration will be estab-
lished, hence allowing the calculation of the FRC.
Helium (He) is traditionally chosen as the tracer gas in 
multiple breath gas dilution methods as it is easily measur-
able in low concentrations with the degree of accuracy 
required and the analysers require little maintenance.
To calculate the unknown value (FRC), the following 
equation can be used:
FRC=V1 × ((He1 − He2)/He2)
where V1=circuit vol, He1=initial helium concentration 
and He2=final helium concentration.
All measurements are made at ambient temperature, 
pressure and saturated with water vapour. The appro-
priate correction factor must be applied to allow values 
to be reported at BTPS. If the equipment used does not 
have a built- in thermometer and barometer to automati-
cally correct for room temperature and PBOX, then these 
variables should be entered into the software prior to 
testing.
equipment
For this steady- state method the basic components of 
a closed circuit include a spirometer (eg, a rolling- seal 
spirometer), a circulating pump, helium analyser, O2 
source and CO2 absorber. An O2 analyser is desirable, but 
not essential. Most equipment are now fully computer-
ised, but the test conditions should be easily configurable 
by the operator. Optimum equipment characteristics are 
shown in the ‘Equipment specifications: helium dilution’ 
section).
Quality control
The volume calibration of the spirometer should be 
checked daily and its linearity weekly. The helium analyser 
should be calibrated daily, and should be checked for 
linearity on a quarterly basis with different gas mixtures 
within the usual measurement range. Alternatively, the 
change in helium concentrations can be recorded when 
a known volume of air is introduced into the circuit 
from a calibration syringe. The volume of air added can 
be calculated from the helium dilution using the FRC 
equation (see ‘Measurement principles’ section) and 
compared with the actual volume introduced, although 
care should be taken with applying the correct volume 
correction factor if calculated using the manufacturer’s 
software.
Tubing should be checked regularly for leaks and the 
CO2 absorber replenished as soon as signs of colour 
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change are observed (CO2 absorber mediums usually 
have a colour indicator that changes colour when the 
absorber is depleted). Manufacturers usually suggest 
changing the absorber after a predetermined number 
of tests. All other cleaning and maintenance should be 
carried out on a regular basis as recommended by the 
equipment manufacturer.
measurement procedure
The closed circuit is prepared according to the manufac-
turer’s instructions with the appropriate volume, which 
is a mixture of air, oxygen and helium (typically using a 
cylinder of premixed gas containing 14% helium, 18% O2, 
balance air). This represents volume V1 and comprised 
the dead space of the equipment and the total volume of 
gas in the circuit. The gases are mixed within the circuit 
by the circulating pump, and the helium concentration 
should be recorded once the circuit has been allowed to 
stabilise (He1).
The subject, wearing a noseclip, should be given 
adequate time for their breathing to adapt to the mouth-
piece before the measurement of FRC begins. They 
should then be switched into the system at the end of 
a normal tidal exhalation. The subject should continue 
to breathe tidally through the mouthpiece throughout 
the test. Ideally the patient should not be able to see the 
chart trace or the computer screen during measurements 
as this can influence their breathing pattern. The volume 
of the circuit is maintained by either manual or auto-
matic addition of O2 as it is consumed and also to replace 
the CO2 which has been absorbed (figure 14).
The helium concentration should be observed 
throughout the test and equilibrium will be considered 
to have been reached when the helium concentration 
varies by ±0.02% (if absolute values are displayed) or 
FRC varies by ±0.025 L (if FRC is displayed) over a 30 s 
period.4 This is the He2 value, which is required for the 
subsequent calculation of FRC. If the readings have not 
stabilised after 10 min have elapsed, then the readings 
should be noted at this point and the fact that a stable 
reading has not been achieved should be recorded.
Once a stable FRC (or helium) reading has been estab-
lished (or after 10 min if no stable readings have been 
achieved), the subject should be asked to perform a 
relaxed ERV manoeuvre, followed by an IC manoeuvre 
and then a VC manoeuvre. In patients with significant 
airflow obstruction, sufficient time should be allowed for 
the patient to return to FRC in between manoeuvres to 
negate the effects of air trapping. The highest technically 
acceptable values for ERV, IC and VC should be used for 
subsequent calculations. Depending on the equipment 
(and software) used, the VC, IC and ERV manoeuvres may 
be performed at the start of the test or at the end after 
a stable FRC has been established. Measurements made 
after the determination of FRC are of greater physiolog-
ical relevance. Up to three measurements of ERV may be 
performed, with the mean of all technically acceptable 
ERV manoeuvres used in subsequent calculations.79
repeatability criteria
Evidence suggests that the intertest variability is so small 
that only one test needs to be performed; however, more 
attempts will improve accuracy.79 If a second measure-
ment of FRC is to be made, there should be an interval 
equivalent to the duration of the first measurement (or 
10 min, if no stable FRC was obtained) before the second 
measurement begins. The value quoted for FRC should 
be a mean of the two values, assuming that there is no 
significant difference (ie, <0.2 L between the values). 
Repeatability between technically acceptable meas-
urements should be within 10% and the average value 
quoted. The highest values for ERV and IC from the two 
measurements should be used to calculate the subdivi-
sions of lung volume.
equipment specifications: helium dilution
Spirometer
The spirometer is capable of recording volumes ≥8 L with 
an accuracy of ±3.0%. If a flow transducer is used for the 
measurements, then this needs to be calibrated using gas 
of identical composition to that used during testing to 
compensate for changes in gas density.
The equipment volume should be kept as low as possible 
as this will increase the accuracy of the measurements. 
With no gas in the spirometer the volume of the equip-
ment (including valves, analysers and breathing tubes) 
should ideally be <4.5 L.4 The volume of the patient’s 
mouthpiece and any disposable bacterial/viral filter 
should also be kept as low as possible (ideally <0.1 L).
Helium analyser
Most equipment use thermal conductivity (katharom-
eter) helium analysers, but other types of analysers can 
be used,80 as long as they have a fast response time (<15 s 
to respond to a 2% change in helium concentration) and 
a resolution <0.01% over the 5%–15% range of helium. 
There should be very little drift, with the value for helium 
concentration changing by <0.02% in 10 min in a closed 
circuit.
The circulating pump in the circuit should be capable 
of delivering flows of 50–60 L/min.
Gas conditioning agents (ie, desiccators and CO2 
absorbers) should be easily accessible and should be of a 
colour changing type, which will make it easy to identify 
when they are in need of replacement. Replacement of 
gas conditioning agents after a fixed period of patient 
testing is a suitable alternative strategy, but depends on 
adequate laboratory records being maintained.
potential sources of error
The main sources of measurement error when meas-
uring lung volumes by helium dilution are subject error 
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or technical error. With the exception of switch- in errors 
(see Technical errors below), the most common problem 
encountered during measurement is leak. The definition 
of what constitutes a leak has never been published, but 
should be considered when the volume of oxygen added 
to the spirometer circuit exceeds the expected metabolic 
requirements (typically 0.20–0.25 L/min or 0.04 L/kg/
min) or when the system is not maintained at the turn 
in volume. A leak should also be suspected when current 
results for FRC are significantly different from previous 
values for the same subject (even if stability criteria have 
been met), especially if there is no apparent change in 
the subject’s clinical condition.
Technical errors
The most common source of error is that the subject is not 
switched into the circuit at their true FRC, either because 
they were turned in too early or too late; however, most 
modern systems will automatically switch the subject in at 
the appropriate point in the breathing cycle. Small differ-
ences in volume (~50 mL) can be discounted as being 
of limited clinical significance, but larger differences 
(>500 mL) should result in the test being abandoned and 
then restarted after the equipment has been checked 
for leaks and reset. For differences between 50 mL and 
500 mL, the subject should be maintained at the switch- in 
volume and the difference subtracted (or added) to the 
measured FRC after the test is completed.
Equipment leaks can occur almost anywhere in the 
system, but the most likely places are in breathing tubes 
and around absorbers. Breathing tubes can be checked 
for leaks by plugging both ends of the tube securely to 
ensure an airtight fit and immersing the tubes fully in a 
container of water and watching for bubbles. Any tubes 
showing signs of leaks should be discarded immediately.
Leak checks of the system (as described by the equip-
ment manufacturer) should always be carried out after 
absorbers have been changed, as these are frequently a 
source of leaks. Removal and reinsertion of the absorbers 
often solves the problem.
Subject error
Leaks are most common around the mouthpiece or due 
to loose- fitting noseclips. A wider flanged mouthpiece 
and tight- fitting noseclips will minimise leaks. If a subject 
has perforated eardrums (and this should always be 
suspected if a leak occurs), using disposable gas imper-
meable earplugs should prevent this problem. Close 
observation and regular reminders to keep a tight seal 
against the mouthpiece will help to reduce the incidence 
of subject leaks.
meAsurement oF cArbon monoxIde trAnsFer FActor
Introduction
The primary function of the lungs is to exchange gas 
between the atmosphere and the pulmonary circula-
tion. The ability of the lungs to exchange gas across the 
alveolar capillary membrane is determined by its struc-
tural and functional characteristics. Structurally these 
include lung volume, path length, membrane thickness, 
the surface area of the lungs and the capillary blood 
volume. Functionally it is influenced by the level of 
ventilation and perfusion of the lung and its matching, 
haemoglobin (Hb) levels, blood transit time, the alveolar 
capillary membrane characteristics and the chemical 
reaction rate with Hb (θ). In the lung function labora-
tory, CO is used as a surrogate for oxygen. CO is an ideal 
test gas because it has the same diffusion coefficient and 
rate of reaction with Hb as oxygen, binds to the same site 
on the Hb molecule, and their respective Hb dissociation 
curves are affected in the same way by temperature, O2, 
CO2, pH and 2–3 diphosphoglycerate (DPG). In addi-
tion, its high affinity for Hb (210 times that of oxygen) 
means that the PO2 remaining in the physiological state 
does not influence the measurement. Additionally, CO is 
safe to breathe at low concentrations and easy to measure 
by infrared/electrochemical analysis.
The Roughton and Forster equation from 195781 parti-
tions alveolar- capillary diffusion of oxygen and CO into a 
membrane component (Dm), a red cell component (θ) 
and a capillary blood volume component (Vc).
Equation 1, the Roughton and Forster equation:
1/Tl=1/Dm+1/θ.Vc
where Tl is the transfer factor, Dm is the membrane 
diffusing capacity, θ is the rate of reaction of CO with Hb, 
and Vc is the capillary blood volume in contact with the 
inhaled CO.
Although there is more than one technique for 
measuring CO uptake (and it is acknowledged that other 
techniques have been tried), this section will describe 
the single- breath technique, which is the most widely 
adopted and the one for which regression equations are 
readily available.
definitions
 ► TLco: transfer factor, the product of Kco and VA.
 ► Kco: transfer coefficient, the rate of transfer of gas 
between the alveoli and the erythrocytes into the alve-
olar capillaries.
 ► VA: alveolar volume, the volume of the lungs during 
the measurement of gas transfer.
 ► VIN: volume inspired, the volume of test gas inhaled 
during the measurement of gas transfer.
 ► Dm: the diffusing membrane capacity.
 ► Vc: the pulmonary capillary blood volume.
 ► θ: theta, the chemical reaction rate of CO with Hb.
measurement principles
Gas transfer is governed by Fick’s law of diffusion, 
which states that ‘the rate of transfer of a gas through 
a membrane of constant thickness is proportional to its 
surface area (A) and the difference in gas partial pressure 
between the two sides (P1−P2), and inversely proportional 
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Table 5 Gas transfer equipment specification by sampling method
System type
Required specification
Rapid gas analyser systems Discrete sample systems
Analyser specification
0%–90% response time
150 ms N/A
Maximum non- linearity ±1% of full scale ±1% of full scale
Accuracy Within ±1% of full scale Within ±1% of full scale
Interference from 5% CO2
or water vapour
<10 ppm error in CO <10 ppm error in CO
Drift for carbon monoxide <10 ppm over 30 s <10 ppm over 30 s
Drift for tracer gas <0.5% of full scale over 30 s <0.5% of full scale over 30 s
Flow accuracy ±2% over the flow range −10 to 10 L/s ±2% over the flow range −10 to 10 L/s
Volume accuracy (3 L syringe) Within ±75 mL Within ±75 mL
Barometric pressure sensor 
accuracy
Within ±2.5% N/A
Ability to perform a QA check Calculate (Alveolar Volume) VA of 3±0.3 L 
and TLco of <0.166 mmol/min/kPa
Calculate VA of 3±0.3 L and TLco of 
<0.166 mmol/min/kPa
Circuit resistance <1.5 cmH2O/L/s <1.5 cmH2O/L/s
Equipment dead space Known and <200 mL Known and <200 mL
Leak No leak No leak
Adapted from Graham et al.7
CO2, carbon dioxide; CO, carbon monoxide; N/A, not available; ppm, parts per million; QA, quality assurance; TLco, carbon monoxide 
transfer factor; VA, Alveolar Volume.
to the membrane thickness (t)’. Consequently, TLco is 
the product of the rate of CO uptake (Kco) and the alve-
olar volume (VA) (see equation 2).
Equation 2, Fick’s law of diffusion:
dV/dt=A/T×D×(P1−P2)
Volume of gas (per unit time)=area/thickness × diffu-
sion constant × (partial pressure 1 – partial pressure 2).
CO uptake is measured as a concentration fall in alve-
olar CO per unit time per unit driving pressure. Alveolar 
volume is determined by the dilution of a tracer gas in 
the RV and the volume of gas inspired (VIN). Analysis of 
Kco and VA individually provides information on disease 
pathology that would not be identified by the use of TLco 
alone.
The SI units of transfer factor are mmol/min/kPa and 
represent the uptake of a gas (mmol/min) per unit pres-
sure gradient (kPa). The SI unit of transfer coefficient 
(Kco) is mmol/min/kPa/L. The ATS continues to prefer 
traditional units of mL/min/mm Hg. To convert from 
SI to traditional units, divide by 0.335. To convert from 
traditional units to SI, divide by 2.987.
single-breath technique
Equipment specifications
The ERS/ATS technical standards7 provide detailed 
information with regard to the required equipment spec-
ifications for gas transfer measurement devices. Table 5 
summarises this information and details the minimum 
equipment specification by system with discrete sample 
system referring to the traditional method of measuring 
exhaled sample gas rather than the more modern rapid 
gas analysis method.
Calibration and verification
Volume/flow calibration must be undertaken daily with 
a 3 L syringe across varying flow rates, as per spirom-
etry recommendations. Gas analysers should also be 
calibrated daily using medically certified gases and the 
analyser should be zeroed prior to each test.
Quality control
As detailed in the equations for calculating TLco, the 
ratios of inspired and expired gas concentrations are 
paramount in the determination of gas exchange. It is 
therefore essential that the gas analysers used are linear 
throughout their working range. Linearity assessments 
should be undertaken monthly; however, it is recognised 
that modern systems do not readily enable users to test 
analyser linearity, and there is a call from the ERS/ATS7 
to further evaluate the use of calibration syringes to 
dilute test gas.
Weekly physical and biological control of TLco systems 
should be undertaken. For physical control a TLco test 
should be undertaken using a 3 L syringe in patient test 
mode and according to the manufacturer’s instructions. 
Biological control should be undertaken using a ‘normal’, 
healthy, non- smoking subject. Variability in mean TLco 
should not vary by more than 10%, and errors greater 
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Figure 15 Effects of lung volume on both the TLco and 
the Kco from residual volume to TLC.175 Kco, gas transfer 
coefficient for carbon monoxide; RV, residual volume; TLC, 
total lung capacity; TLco, carbon monoxide transfer factor.
than 10% should result in equipment being evaluated 
prior to further clinical use.82
Test gas composition
The test gas mixture will consist of CO, O2, N2 and the 
tracer gas. The most commonly used tracer gases are 
helium (traditional systems) and methane (rapid gas 
analysis systems). All test gases must be certified as being 
suitable for medical use, and the certificate, gas concen-
trations and gas expiry date must all be visible on the 
cylinder while it is in use.
Test gas composition can alter the measured transfer 
factor, and therefore it is important to standardise the 
concentration used. PAO2 levels influence CO uptake, 
and therefore altering the oxygen concentration in the 
inspired test gas will have an impact on the measured 
transfer factor. For example increasing the fraction of 
inspired oxygen (FiO2) concentration in the test gas from 
0.17 to 0.21 will decrease the measured TLco by between 
8% and 9%.83 It is important to recognise this effect and 
to identify, where possible, the inspired oxygen concen-
trations used to develop the regression equations applied 
and how they may differ. The recent 2017 ERS guideline7 
recommends 21% oxygen be used in the inspired gas 
mix.
procedure
Test considerations
For pretest considerations see the ‘General procedures’ 
section. An additional requirement is to remove supple-
mental oxygen from patients for a minimum of 10 min 
prior to performing the test, when safe to do so, to main-
tain appropriate oxygen saturation (SpO2) levels. Meas-
urements of lung volumes using the nitrogen washout 
technique should be undertaken after measurements of 
gas transfer as this requires inspiration of 100% O2. If 
this is not possible then then a rest interval of twice the 
washout time required to complete the N2 washout test is 
required prior to performing gas transfer measurements 
to ensure complete washout of oxygen.7
Correct performance
The correct performance of gas transfer measurements 
requires the subject to exhale maximally (unforced) to 
RV then inspire maximally to TLC and hold their breath 
for approximately 10 s. This is followed by a complete 
exhalation. The importance of each of these steps is 
outlined in the following sections.
Inspiration
It is important that subjects familiarise themselves with 
the equipment prior to commencement of the measure-
ment. Therefore they should be encouraged to breathe 
tidally, while wearing a noseclip, through the mouthpiece 
for a minimum of five breaths or until normal, steady 
breathing is noted. Once stable the subject is asked to 
exhale to RV.
Once at RV, the patient is connected to the test gas 
mixture and requested to inhale as far as possible. This 
inhalation should be to at least 90% of the subject’s previ-
ously best measured VC.
The influence of lung volume on gas transfer is widely 
known, with decreases in lung volume resulting in an 
underestimation of TLco and an overestimation of Kco 
because the surface to volume ratio for CO increases as 
alveoli become smaller (figure 15) . TLco falls because VA 
falls more than Kco rises. At lung volumes of greater than 
90% of the subject’s VC, both TLco and Kco have reached 
an approximate plateau and therefore further increases 
will have little effect on the estimate. Evidence suggesting 
that lowering the VIN to 85% influences measured TLco 
by less than 5% should be reviewed with caution due to 
the limited number of participants.84 It would be accept-
able to suggest that if technically satisfactory tests were 
obtained but a VIN of 90% was not achieved, data from 
tests where a VIN of 85% or more was achieved could be 
analysed; however, the individual reporting the results 
should be aware of the reduced inspired volume and its 
potential impact on results.85
In addition to the inspired volume requirements spec-
ified above, the inhalation should be rapid and ideally 
achieved within 2 s in normal subjects; however, 85% of 
VIN must be inspired in <4.0 s.
7
Breath hold
The breath hold time should be set at 10±2 s.85 It is 
important that the subject relaxes during breath holding 
and should be encouraged to not breathe out (Valsalva) 
or breathe in (Müller), as this will alter the intrathoracic 
pressure and the pulmonary haemodynamics, resulting in 
either an increase (breathing in) or decrease (breathing 
out) in TLco.
The breath hold time calculation method by Jones and 
Meade is the recommended method. With this method 
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breath hold time is calculated from 0.3 of the inspiratory 
time until halfway through the sample.83
The Ogilvie breath hold method tends to overestimate 
TLco when airflow obstruction is present. This is due to 
the increased time it takes to obtain an alveolar sample 
in airflow obstruction and that the Ogilvie method termi-
nates at the beginning of the alveolar sampling period. In 
contrast the Jones- Meade method includes a proportion 
of the alveolar sample time and consequently offers the 
least overestimation of TLco in the presence of airflow 
obstruction.
Washout and sample collection
During exhalation, following breath hold, the initial 
portion is discarded (washout) since this contains gas 
from the anatomical and instrument dead space.
Systems using a sample collection technique require 
the volume of washout to be set in advance, usually 
between 750 and 1000 mL.83 In patients with small VC 
this value can be reduced to allow sufficient sample 
volume; however, it must be recognised that this will 
inevitably lead to some contamination of sample gas 
with dead space gas, ultimately reducing the measured 
transfer factor.
After the dead space gas has been discarded, a sample 
representative of alveolar gas is analysed. This sample 
volume is typically between 500 and 1000 mL and will 
depend on the response time of the system’s gas anal-
ysers. With traditional systems this means that subjects 
with small VC may require adjustments to the washout 
and sample volumes in order to achieve a result. 
Where settings for washout and/or sample volume are 
reduced, this should be clearly documented to allow 
the individual interpreting the results to acknowledge 
the potential impact on measured values.
Modern rapid gas analysis systems allow the oper-
ator to inspect the continuous exhaled gas concen-
tration curves and more accurately identify the end 
of dead space washout. Huang and Macintyre86 found 
that 50% of patients tested had dead space contami-
nate the sample using the ATS/ERS criteria (arbitrary 
750–1000 mL) when compared with visual analysis of 
exhaled gas concentration; this leads to a falsely low 
TLco measurement. It is therefore vital with these 
systems to inspect the exhaled gas waveforms to ensure 
that the sample is taken from the alveolar plateau, that 
is, the initial fall in exhaled tracer gas concentration 
from inspired values to the plateaus at expired values. 
Rapid gas analysis systems enable the operator to iden-
tify more accurately the end of washout enabling true 
alveolar gas concentrations to be obtained in patients 
with much smaller VC and in those with increased dead 
space.
Time between manoeuvres
Since the previous ARTP/British Thoracic Society guide-
lines1 were published in 1994, there has been little if 
any new evidence with regard to the time required to 
wait in between tests. An interval is required to allow 
adequate time for tracer gas to be eliminated from the 
lungs and prevent interference with subsequent tests. 
In the absence of new evidence the recommendation to 
allow at least 4 min between tests remains. It should be 
recognised that patients with severe airflow obstruction 
may require longer time intervals to completely remove 
tracer gas from their lungs. Failure to achieve reproduc-
ible results in this patient group may indicate this. With 
newer rapid gas analysis systems, by sampling expired CO 
prior to the test sample inhalation, it is possible to deter-
mine the CO baseline so that time between tests can be 
minimal (<2 min).
End of test criteria
A minimum of two technically acceptable gas transfer 
manoeuvres should be performed with a maximum of 
five (see figure 16 for illustration of a technically accept-
able trace). Five gas transfer manoeuvres will increase 
carboxyhaemoglobin (COHb) by approximately 3.5%, 
which will ultimately decrease measured transfer factor 
by 3.5%.87 TLco results should be within the repeatability 
criterion of 0.67 mmol/min/kPa, Kco within 0.10 mmol/
min/kPa/L and alveolar volume within 5%.88 89 The 
mean of two technically acceptable manoeuvres should 
be reported.
Calculations
The transfer factor for carbon monoxide (TLco) equals 
the rate of uptake of CO (changeCO/changet) from alve-
olar gas multiplied by the alveolar volume (VA) at which 
the measurement is made. During the measurement of 
gas transfer, subjects are requested to exhale to RV then 
take a maximal breath in (VIN) during which they inhale 
the test gas. As the tracer gas does not readily pass across 
the alveolar capillary membrane, the dilution of tracer 
gas is proportional to the volume of gas in the lungs prior 
to inhalation (RV).
Alveolar volume can therefore be estimated by the 
following equation:
Equation 3, calculating alveolar volume (VA):
 VA = (VIN − VD)×
F1Tr1
FATr2
× BTPS  
VA is reported as BTPS and is converted to standard 
temperature (0°C or 273 K) and pressure (760 mm Hg) 
and dry (no water vapor) (STPD) for the purpose of 
calculating TLco (see equation 4), FICH4 is the initial 
tracer gas concentration and FACH4 the final tracer gas 
concentration. VD is the dead space of the measuring 
system.
In the 1994 guidelines1 an alternative calculation for 
VA was proposed as VA=RV+VIN. This was suggested as an 
alternative and more accurate estimate of VA in patients 
where large differences between VA and TLC were 
observed due to maldistribution of inspired gas. However 
the TLco equation is based on the volume of gas that the 
tracer gas distributes into and not necessarily the TLC. It 
cannot be presumed that the Dm and Vc properties of the 
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Figure 16 A technically acceptable TLco trace. Reproduced from Hughes, ‘Physiology and Practice of Pulmonary Function’, 
published by the Association for Respiratory Technology & Physiology. TLco, carbon monoxide transfer factor. FACO, 
Fraction of Carbon Monoxide in Alveolar Gas. FAHE, Fraction of Helium in Alveolar Gas.
unmeasured lung regions are identical to those directly 
measured regions, and for this reason the use of VA calcu-
lated in this way is no longer advocated. For quality assur-
ance purposes the measured VA should be compared 
with the subject’s measured TLC and should always be 
less. Large discrepancies between the two (>500 mL) are 
suggestive of maldistribution of inspired gas.
Equation 4, calculating gas transfer (TLco):
The following equation demonstrates how transfer 
factor is determined from VA and Kco.
 VA × Kco = VCO  
 units mL (STPD)× min−1 = mL/min−1 
To obtain TLco both sides are divided by Pb* (baro-
metric pressure less water vapour pressure at 37°C in alve-
olar gas).
Equation 5:
 Tlco=
VAxKCO
PB*  
units mL (STPD)×min/mm Hg=mL/min/mm Hg
During breath holding, CO is removed from alveolar 
gas at an exponential rate [loge (CO0/COt)/BHT], 
where CO0 and Cot are the alveolar concentrations at the 
start and finish of the breath holding time (BHT).
Equation 6:
 
TLCO=
VA
t xPb*
x ln
[
FACO0
FACOt
]
 
The test assumes that both CO and the tracer gas are 
diluted equally on inspiration, and therefore the concen-
tration of CO in the alveoli (CO0) can be calculated by 
the ratio of the inspired tracer gas (Tr1) and the alveolar 
tracer gas (Tr2) concentrations.
Equation 7:
 FACO = FICO×
Tr2
Tr1  
where FICO is the inspired concentration of CO and 
FACO is the fractional concentration of CO in the alveoli 
prior to breath holding.
Equation 8:
The equation for TLco now becomes:
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TLCO =
VA
t× pb∗ × In
[
FICO0
FACOt
xTr2Tr1
]
 
Equation 9:
If VA is converted to STPD conditions and SI units 
(mmol/min/kPa), the equation becomes:
 
TLCO = VA(STPD)t×(pb∗−6.28) × In
[
FICO0
FACOt
xTr2Tr1
]
x6000022.4  
where 60 000 arises from the conversion of seconds to 
minutes and litres to millilitres, and 22.4 from the conver-
sion of millilitres (STPD) to mmol.
Equation 10, calculation of Kco:
As demonstrated in equation 6, the calculation of 
Kco is determined from the logarithmic change in CO 
concentration during breath hold divided by t and the 
Pb of dry gas.
 
TLCO=VAx
(
1
t xPb*
xln
[
FACO0
FACOt
])
 
units mol/min/kPa/L(BTPS).
correction for hb concentration
As part of the Pathology Harmonisation Initiative in 
2012, the units of measurement for Hb were standard-
ised to g/L.90 If a subject’s Hb is >190 g/L or <117 g/L, 
then the adjusted transfer factor will be 10% lower or 
higher respectively than that recorded. It is desirable that 
measurements of TLco be reported at a standard Hb of 
146 g/L for adult men and adolescents and 134 g/L in 
adult women and children <15 years.91 92
The following is the equation for adult men and 
adolescents:
 Tlco, ad = Tlco, ob[(10.22 +Hb)/(1.7 ∗Hb)] 
The following is the equation for adult women and 
children <15 years:
TLco,ad=TLco,ob [(9.38+Hb)/(1.7*Hb)]
 Tlco, ad = Tlco, ob[(9.38 +Hb)/(1.7 ∗Hb)] 
where TLco,ad and TLco,ob are the adjusted and 
observed TLco, respectively, and Hb is the patient’s 
measured Hb concentration. It should be noted that 
these equations were developed using Hb in g/dL and 
therefore Hb values in g/L will need to be adjusted to 
g/dL (Hb g/dL=Hb g/L/10) prior to putting them into 
the equation. If a correction for Hb concentration has 
been made, then this should be made clear on the report 
form.
correction for co concentration
CO inhalation from pollution or cigarette smoking 
forms COHb, which will influence measured transfer 
factor values. First, by occupying Hb binding sites, it 
produces an ‘anaemia effect’, lowering the measured 
gas transfer value. Second, increased partial pressure of 
CO in the blood will reduce the driving pressure for CO 
diffusion between the alveoli and the capillary blood. 
The impact on measured TLco is a 1%–2% reduction 
for every 1% increase in COHb.16 17 As endogenous 
COHb (1%–2%) would have contributed to the meas-
ured TLco values used to generate predicted equations, 
adjustment for COHb is only recommended when 
COHb values are greater than 2%.
Correction for CO:
 Tlco, ad = Tlco, obx[(1 + FACO)/560] 
transfer factor for nitric oxide
The transfer factor of the lung for nitric oxide (Tlno) is 
potentially of interest. However, at present this technique 
is not used in routine respiratory assessments. Despite a 
number of clinical papers suggesting its usefulness, there 
is further work needed.
blood GAs AnAlysIs
Introduction
Blood gas sampling and analysis play a vital role in the 
diagnosis of clinical problems and monitoring of possible 
treatment modalities such as supplemental oxygen (O2) 
or assisted ventilation.
Blood gas analysis can measure several indices, which 
can aid diagnosis when interpreted in relation to the clin-
ical state of the patient. Blood gases reflect the ability of 
the cardiopulmonary system to maintain the relationship 
between cellular respiration and supply of O2 and elimi-
nation of carbon dioxide (CO2) via the lungs.
nomenclature
This nomenclature was taken from Rowe and 
Arrowsmith93 (A, alveolar; a, arterial; Fi, inspired frac-
tion; P, partial pressure exerted; S, saturation).
Directly measured
 ► PaO2: measured using a polarographic (Clark) elec-
trode. Hb is the major carrier of O2, each molecule 
binding four molecules of O2. A small amount of 
O2 is dissolved in blood, but it is this fraction that 
diffuses through capillaries to supply tissues. PaO2 is 
the partial pressure of undissolved oxygen, which is 
in equilibrium with dissolved oxygen.
 ► PaCO2 : measured using a Severinghaus electrode. 
CO2 is carried as bicarbonate (60%), with proteins 
(30%) and dissolved (10%).94
 ► pH: measured using a pH electrode. pH=−log10 
([H+]): the negative logarithm of [H+]. pH falls as 
[H+] rises. pH 7.0 corresponds to [H+] 100 nmol/L. 
A change of one pH unit represents a tenfold change 
in [H+].
Derived
 ► Actual HCO3: the actual amount of bicarbonate 
contained in a sample. Plasma is equilibrated with 
partial pressure of carbon dioxide (PCO2) 5.3 kPa 
(40 mm Hg) at 20°C and actual HCO3
− calculated 
from the volume of CO2 evolved when acid (HCl) is 
added to the sample.
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Figure 17 Acid- base nomogram.175 PCO2, partial pressure 
of carbon dioxide.
Table 6 Blood gas reference values
Units Range Units
pH 7.35–7.45
PCO2 4.8–6.0 kPa
PO2 10.0–13.5 kPa
SaO2 95.0–98.0 %
[HCO3] 22.0–26.0 mmol/L
Base excess −2.0–3.0 mmol/L
HCO3, bicarbonate; PCO2, partial pressure of carbon dioxide; PO2, 
partial pressure of oxygen; SaO2, arterial oxygen saturation.
 ► Standard HCO3
−: this is the concentration of bicar-
bonate when the sample is equilibrated with PCO2 
5.3 kPa (40 mm Hg) at 37°C, and with Hb fully satu-
rated with O2. The effects of respiratory acidosis/alka-
losis are eliminated.
 ► Base excess: the quantity of strong acid (or base) 
required to titrate 1 L of blood back to pH 7.4 at 
PCO2 5.3 kPa (40 mm Hg) and 37°C.
 ► FiO2: the fraction of oxygen in inspired gas especially 
that supplied as supplemental oxygen via a mask or 
nasal cannula. The alveolar gas equation can be used 
to predict the greatest partial pressure of oxygen in 
alveoli (PAO2) that can be achieved for a given FiO2. 
In normal, the difference between PAO2 and PaO2 is 
usually small (<1 kPa/7 mm Hg). The FiO2 must be 
known to assess the adequacy of oxygenation.
 PAO2 = FiO2 × (PB − PH2O)−
PACO2
RQ  
The alveolar gas equation: assuming barometric pres-
sure (PB)=101 kPa; saturated water vapour pressure (PH20) 
at 37°C=6.3 kPa; alveolar CO2 (PACO2)=5.2 kPa; respira-
tory quotient (RQ)=0.8.
 ► SaO2: the percentage of haemoglobin saturated with 
oxygen (oxyhaemoglobin), that is, oxygen saturation.
Acid-base balance
Acid- base balance is tightly regulated by the respiratory 
system and renal system to maintain a pH between 7.36 
and 7.42. The relationship between PaCO2/acid [H
+] and 
bicarbonate/base [HCO3] is shown in figure 17.
blood gas normal ranges
Table 6 shows the blood gas reference values.
measurement of arterial blood gases
National and international guidelines recommend accu-
rate and reliable measurement of arterial blood gases 
(ABGs) that must comply with specific criteria for the 
prescription of long- term oxygen therapy (LTOT).36 95–97 
The ‘gold standard’ technique for blood gas analysis is 
arterial blood obtained via an indwelling arterial catheter 
(most often sited at the radial artery in adults) or by arte-
rial puncture.
By nature of the complexity and invasiveness of arte-
rial catheterisation, this method is usually reserved for 
the intensive care setting where patients may require 
frequent blood gas testing. Technical and safety consid-
erations determine that for most patients who require 
blood gas analysis, placement of an arterial catheter is 
either not justified or only for a limited period (such as 
serial measurements during cardiopulmonary exercise 
testing).
Arterial blood is most often sampled by arterial punc-
ture using a needle and syringe. Although traditionally 
performed by medical staff, arterial sampling is now 
often practised by senior healthcare scientists who have 
met the acceptable competency standards required by 
local policy. Importantly periodic re- evaluation relative 
to common precautions, correct syringe preparation, site 
determination, puncture technique, sample aspiration, 
storage and disposal of blood specimens, as well as post-
puncture care should be performed.98
Equipment
There are now many commercially available arterial 
blood sampling kits available. The sampling kit used in 
any one centre should have been determined based on 
the current understanding of preanalytic phase consid-
erations, which include needle size, anticoagulation type, 
sample collection, handling and transportation, since 
these factors account for up to 70% of all errors in the 
process of collecting and processing a blood sample.99 100
The use of plastic syringes is considered the norm for 
blood collection so an awareness for the potential for 
error in PO2 measurement due to permeability should be 
minimised by maintaining the sample at room tempera-
ture (rather than an ice/water bath) since lowering the 
temperature has a deleterious effect of increasing perme-
ability giving rise to artefactual increase in PO2.
101 Every 
effort should be made to analyse the sample immedi-
ately after it has been drawn (or at least within 15 min 
after sampling) to minimise the in vitro changes in pH, 
PCO2 and PO2 due to contaminating ambient air. It is 
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also well known that air bubbles erroneously introduced 
into blood collected in syringes can affect results. This 
PO2 interference is greater if the air bubble is vigorously 
mixed with the blood, such as by intense shaking or 
pneumatic tube transport.102
A separate problem of analysis delay is posed by the fact 
that blood cells continue to metabolise glucose following 
collection. This glycolysis is associated with oxygen 
consumption and carbon dioxide generation. Therefore, 
reducing the temperature would have a beneficial effect 
of slowing this process; however, this has a positive effect 
of increasing PO2 as mentioned in the paragraph above.
Aspiration of a homogeneous whole blood sample into 
the blood gas analyser requires that the sample be arti-
ficially anticoagulated to prevent clotting. Dry (lyophi-
lised) heparin is the anticoagulant most suitable for blood 
gas testing. Liquid heparin prepared syringes are largely 
avoided due to its diluting effect lowering PCO2 values. 
However, due to the cost of preprepared dry (lyophi-
lised) syringes, the practice of liquid prepared syringes 
still continues in some areas.103 A 2 min programme of 
slowly inverting and rolling the syringe after the sample 
is collected to allow for correct homogeneity is recom-
mended. Inadequate or delayed mixing can result in the 
formation of fibrin and subsequent rejection from blood 
gas analysers.104 105
Calibration and quality control
Calibration of modern blood gas analysers is automated 
and should consist of a one- point calibration every 
1–2 hours and a 2- point calibration every 4–6 hours. 
In addition to calibration, it is essential that blood gas 
analysers undertake quality control measurements. Again 
most automated blood gas instruments will have internal 
quality control built into its system. Quality control is vital 
to identify electrode drift not established by calibration. 
Routinely, quality control solutions are aqueous buffers 
equilibrated to a known PO2, PCO2 and pH across a range 
of physiological reference ranges, including acidaemia, 
alkalaemia and hyperoxia. A limitation of aqueous buffers 
is that they do not have the viscous properties of blood. 
Quality control with tonometered bovine blood is consid-
ered the gold standard for assessing analyser accuracy.
Guidelines106 recommend that point- of- care users 
should participate in an external quality assurance 
programme in addition to internal QC. These schemes 
provide an external assurance that blood gas analy-
sers are performing within an expected range. They 
aim to measure systems for precision and accuracy, 
using defined standards to supplement internal quality 
control.
Procedure for radial artery puncture
Allen’s test
The modified Allen’s test should be performed prior 
to taking an arterial blood sample to determine arterial 
competency via the ulnar artery in the unlikely event of 
radial artery thrombosis.
 ► The patient should be instructed to clench their fist 
tightly.
 ► The operator should then apply occlusive pressure to 
both the ulnar and radial arteries, to obstruct blood 
flow to the hand.
 ► While applying the occlusive pressure to both arteries, 
have the patient relax the hand, and check if the 
palm and fingers have blanched. If this is not the case 
not enough pressure has been applied to occlude the 
arteries.
 ► Release the pressure on the ulnar artery only, to 
determine whether the test is positive or negative.
 ► A positive test—if the hand flushes within 5–15 s—
indicates that ulnar circulation is viable.
 ► A negative test—if the hand does not flush within the 
same time frame—indicates the ulnar circulation is 
not viable and arterial sampling of the radial artery 
should not occur.
Other relative contraindications to performing an 
arterial sample include inflammation, infection or poor 
integrity at the selected puncture site and Raynaud’s 
phenomenon.
Pretest considerations
Previous evidence supports that patient experience could 
be greatly improved if four areas of consideration were 
addressed107:
 ► Pain caused during the procedure.
 ► Competence of practitioners performing the test.
 ► Good pretest provision of information.
 ► Concern regarding changes to treatment in the long 
term.
An undesirable characteristic of arterial sampling is 
the pain experienced by the patient. The use of a local 
anaesthetic such as lidocaine proves to be a contentious 
one with a high degree of anaesthetists advocating its 
use, but far fewer non- anaesthesia providers using it.108 
In a study of 270 subjects it was shown that subcuta-
neous infiltration of a local anaesthetic before arterial 
puncture reduced pain by more than 50%.109 The use 
of topical, local anaesthetic such as Emla cream has 
shown mixed opinion of effectiveness compared with 
local injection. Its application is largely non- logistically 
acceptable due to its time to work of between 40 and 
60 min. ABG analysis in most settings is often required 
in a more timely manner than topical anaesthetic will 
allow.
The variance reported by patients regarding the care 
provider’s ability to perform ABG sampling raises the 
importance of training issues to improve skills and imple-
ment best practice at local level. Patients need to be 
confident in the healthcare professional they see and in 
the standard of care received.
Robust information concerning the procedure itself 
must be provided. This may help to reduce anxiety and 
pain levels experienced by patients and provide more of 
an association of the clinical procedure with treatment 
the patient may receive as a result of the procedure.
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Health and safety considerations
All blood should be regarded as potentially infective 
and therefore disposable surgical gloves should be worn 
when sampling blood. Health and safety issues need to 
be considered when using needles. In order to prevent 
needle stick injury, the operator should not resheathe 
the needle; it should be disposed of in a sharps box 
immediately after use. If a needle stick injury occurs, the 
wound should be squeezed to encourage bleeding and 
washed out thoroughly. The hospital policy for a needle 
stick injury would need to be followed. Blood samples 
should also only be taken in designated work areas where 
it is safe to do so and any blood spillage that occurs 
should be dealt with according to departmental policy. 
If a spillage has occurred, access to that area should be 
restricted until it has been cleaned. Glass capillary tubes 
should also be disposed of in a sharps bin after analysis 
of the sample.
Consent
Appropriate information about the procedure including 
any benefits and risks and what treatment may result 
as a consequence of the sampling procedure must be 
conveyed. Prior to blood sampling the patient must be 
capable of providing voluntary consent.
Sampling procedure
Palpate both radial pulses and select the pulse that is 
the most prominent. Perform the modified Allen’s test 
to ensure adequate collateral circulation. The syringe 
and needle should be prepared and the syringe cap used 
to ensure sterility. Stabilise the wrist with use of a pillow 
and clean the puncture site with a suitable skin prepara-
tory wipe. Remove the cap from the needle and present 
the tip to the puncture site inserting at a 35°–45° angle. 
Pierce the skin and slowly advance the needle in one 
plane. When the artery is punctured, blood will enter 
the syringe. If the needle goes through the vessel, slowly 
withdraw the needle until blood appears again in the 
syringe. After enough blood has filled the syringe (which 
will be dictated by the volume needed for correct hepa-
rinisation), withdraw the needle and immediately apply 
pressure directly on the puncture site with sterile gauze 
or cotton wool for 5–10 min. Failure to do this may cause 
haemorrhage or thrombosis. Remove the pressure pad 
and check that it is possible to palpate a pulse distal to 
the puncture site.
To prepare the sample for analysis, hold the syringe 
vertically, gently tap the barrel and advance the plunger 
until it forces air bubbles out of the syringe. Remove 
the needle and cap the syringe and then gently roll 
and invert the syringe to aid mixing of heparin. The 
sample should be analysed straight away or at least 
within 15 min at room temperature. The FiO2 should 
be recorded in addition to any ventilatory indices that 
may apply.
Possible complications
Adopting the correct procedure for arterial sampling will 
help to minimise any complications following the proce-
dure:
 ► Correct aseptic sampling will aid in reducing infection. 
A sterile technique will help to ensure no pathogens 
are passed directly into the patient’s bloodstream.
 ► Bleeding from the artery into the surrounding tissue 
can occur if insufficient time or pressure is applied to 
the puncture site. The resulting haematoma can be 
worse if sampling has been performed on a patient 
managed with an anticoagulant such as aspirin or 
warfarin. Even after anticoagulation therapy has 
ceased, there is a period of washout that needs to be 
observed.
 ► Trauma to the artery following its puncture can result 
in a thrombus, which could subsequently block blood 
flow. Performing the Allen’s test and checking for a 
pulse distal to the puncture site can help minimise 
this complication.
 ► The radial and brachial nerves run adjacent to 
the artery and if the needle is inadvertently passed 
through them, peripheral nerve damage can occur.
 ► Practitioners should be aware of the possibility of a 
vasovagal response during or immediately following 
arterial sampling and observe the patient carefully.
capillary blood gas sampling
Acknowledging the invasive nature and discomfort 
that can be associated with direct arterial puncture, 
the method of arterialised earlobe capillary sampling 
can be used as an alternative method to determine pH, 
PCO2 and PO2. It is the least invasive and safest blood 
collecting technique and can be performed by all health-
care personnel following suitable training.110 The relative 
simplicity and safety profile of capillary blood sampling 
and the necessity for only small volumes (90–150 µL) of 
blood make the method an attractive substitute for arte-
rial sampling. However, the clinical value of capillary 
blood gas results depends on the extent to which pH, 
PCO2 and PO2 of capillary blood accurately reflect pH, 
PCO2 and PO2 of arterial blood.
Theoretical considerations
The validity of obtaining capillary blood gas samples for 
clinical value remains contentious. There is evidence 
showing that earlobe sampling can be a direct replace-
ment for arterial pH, PCO2 and PO2 if performed prop-
erly; however, it has also been postulated that if preci-
sion is required, this method should not be relied on 
for determination of PO2 when conducting LTOT assess-
ment.111–113
Of paramount importance is the theoretical under-
standing of the relationship between arterial and capil-
lary blood when earlobe sampling. Blood obtained by skin 
puncture is not actually representative of pure capillary 
blood, but a mixture of blood from punctured arterioles, 
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capillaries and venules (as well as a variable contribution 
of interstitial fluid and intracellular fluid from damaged 
tissue cells). However, due to the relative high pressure 
on the arterial side of the circulation, this blood mixture 
contains a greater proportion of blood from the arteriole 
side of the capillary bed than the venule side. Therefore, 
a capillary sample approximates closer to arterial blood 
than venous blood. It is this arteriovenous (AV) differ-
ence which represents the major determinant between 
arterial and capillary blood gas values. The magnitude 
of the AV difference for PO2 is greater than PCO2 and 
pH and represents the problem for insufficient accu-
racy when determining the strict threshold criterion for 
LTOT provision.
Arterial PO2 should be higher than PO2 of arterialised 
blood flowing from the earlobe following piercing because 
the skin capillary bed from the earlobe uses oxygen. Also 
acknowledging that arterialised earlobe samples gener-
ally underestimate arterial PO2 due to AV difference but 
that reduced PO2 is associated with a reduction in AV 
difference, there is good theoretical reason to suppose 
that capillary and arterial blood PO2 agree more closely 
if arterial PO2 is reduced than if normal or raised.
114 In 
the resting state, oxygen utilisation and carbon dioxide 
production will remain relatively constant. Increasing 
blood flow through capillaries has the effect of reducing 
the AV difference and subsequently the capillary/arterial 
difference for pH, PCO2 and PO2. This can be achieved by 
warming the site of puncture with a vasodilating agent to 
ensure optimal arterialisation of the capillary bed. With 
this in mind it is conceivable that under most capillary 
blood gas sampling situations, the difference between 
arterial and arterialised values is minimal.115 However the 
accuracy of capillary blood gas sampling is diminished in 
more hypoxaemic patients and underestimation of the 
true PaO2 can result in overprescription of LTOT.
114
Sampling procedure
The procedure should be explained in full and any 
questions answered. Ensure that the patient has been in 
a rested state for at least 20 min prior to sampling; this 
includes no change to FiO2 or ventilator settings for 
30 min. The FiO2 or prescribed oxygen flow should be 
noted. Reference should be made to the respiratory rate, 
position or level of activity, and the clinical appearance 
of the patient.
The hair should be tied back, any earring or piercing 
in the area to be sampled should be removed, and the 
patient’s clothing protected by covering the shoulder.
The earlobe to be sampled should be primed with a 
vasoactive agent for at least 15 min prior to sampling. The 
inferolateral aspect of the pinna should be presented with 
a preparation containing nicotinate to ensure sufficient 
warming and vasodilatation of the area. (Topical analgesic 
preparations containing only salicylate may not have adequate 
rubefacient properties so it is unclear whether alternative prod-
ucts will produce sufficient ‘arterialisation’ of the capillaries to 
produce accurate results.)
The cream is removed with gauze or wool and vigor-
ously rubbed again, followed by cleaning with suitable 
skin preparation. This rubbing aids to increase local 
circulation and sampling.
The earlobe is then held at 90° to the head with the aid 
of a bung or wool, and using a sterile manual, or auto-
mated, lancet of no less than 3 mm a stab is made approx-
imately 3 mm from the edge of the earlobe. Proper 
technique will negate the requirement for multiple 
incisions.
A good flow of blood should be generated from the 
puncture site. The initial purge of blood should be wiped 
away and then the collection/capillary tube used (which 
depends on sample volume and analyser) introduced 
into the drop of blood that forms. The tube should have 
a dry phase heparin preparation on the internal walls. 
Care should be taken to ensure that the tube is central to 
the drop of blood to ensure an anaerobic sample is taken. 
The earlobe can be gently ‘milked’ by gently stroking to 
encourage blood from the puncture. The tube should be 
held horizontal to the puncture site and blood will flow 
into the tube by capillary action. Any visible air bubbles 
that may pass into the tube must be removed by blotting 
on gauze or wool. Great care must be made not to squeeze 
as this may introduce interstitial and intracellular fluid 
from damaged tissue cells and affect blood values.
Good presample preparation and sampling tech-
nique should ensure that the blood sample is collected 
within 30 s. The sample tube should be filled to minimise 
contact with air in the collected sample. The patient 
is asked to hold gauze or wool to the puncture site for 
several minutes to ensure that bleeding stops. A plaster 
may be used if required. The blood sample should be 
kept at room temperature and sampled as quickly as 
possible to avoid coagulation and ambient temperature 
equilibration.
pulse oximetry
Pulse oximetry is a non- invasive technique for moni-
toring SpO2 either continuously or as a ‘spot check’. 
Pulse oximeters are often used for serial or continuous 
measurements of SpO2 and pulse rate during physiolog-
ical tests.
The SpO2 (%) measured by pulse oximetry is not always 
identical to the actual arterial oxygen saturation (SaO2); 
there is potentially a ±2%–3% error in SpO2 measure-
ments, but generally the two readings are considered 
close enough for clinical purposes. Pulse oximetry simul-
taneously measures the pulse rate (beats per minute), but 
users should be aware that artefact can also give rise to 
incorrect readings and that it may not necessarily corre-
spond to actual heart rate.
Commonly the sensor is placed on a thin part of the 
patient’s body, usually a fingertip, toe or earlobe, or in 
the case of an infant, across a foot. The device passes two 
wavelengths of light (red and infrared) through the capil-
lary bed to a photodetector. It measures the changing 
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absorption of each of the wavelengths (typically 660 nm 
and 940 nm), allowing it to determine the absorption due 
to the pulsing arterial blood alone, while excluding the 
confounding effects of venous blood, skin, bone, muscle 
and fat.
As with any recording, it is essential that the inspired 
oxygen (or room air) and whether or not the patient is 
ventilated is recorded, which is key to the interpretation 
of any recorded data.
Measurement procedure
The precise nature of the set- up depends on the actual 
application being undertaken. However, in general:
 ► The patient should be rested for at least 5 min prior 
to the measurement.
 ► Remove nail polish and artificial nails before using 
a finger probe. Determine if earlobe piercings will 
affect measurements if using the earlobe.
 ► Ensure there is good circulation to probe site: check 
for cold hands or known circulation problems.
 ► If supplemental oxygen is being used record the flow 
or percentage. Also if the patient is on a ventilator or 
Continuous Positive Airway Pressure (CPAP), record 
the settings being used.
 ► Check the quality of the pulsatile signal by checking 
the oximeter heart rate agrees with the palpated 
pulse of the patient and/or reviewing the pulse pres-
sure signal.
 ► The probe should be left in situ for at least 30 s before 
taking a reading.
Calibration, quality control and accuracy
Pulse oximeters are calibrated during manufacture by 
comparison with direct measurements of oxyhaemo-
globin saturation. Current commercial pulse oximeters 
are calibrated using data from healthy volunteers where 
an ABG sample has been obtained. Very few normal 
subjects are studied at an SaO2 of <80%, so in general 
the accuracy of a given pulse oximeter is usually within 
±2% over the range of 80%–100%. Below 80%, the accu-
racy is estimated by extrapolation and therefore is subject 
to poorer accuracy >±2%.
Other technical considerations
There are a number of considerations that can limit the 
effectiveness of oximetry:
 ► Blood flow: the measurement site must be perfused 
such that the pulsatile waveform and the actual blood 
flow can be detected. Reduced blood flow can be 
present in peripheral circulatory disorders such as 
Raynaud’s disease, simply having cold hands, or even 
if a patient just lies on their arm during long- term 
monitoring.
 ► Sampling rate: the sampling frequency used can vary 
between one sample every second to one sample 
every 8 s, and in some models of oximeter can be 
adjusted. The correct sampling rate needs to be 
appropriate to the application for which it is being 
used. For example, in an overnight sleep study, a 
patient with severe sleep apnoea requires a relatively 
high sampling rate to reflect the fast changing signal. 
Sampling rates may also be governed by the memory 
capacity and data storage capabilities of the equip-
ment being used.
 ► Averaging time: oximetry measurements are smoothed 
by performing a ‘running average’ with a moving 
window that varies from 1 to 15 s in length, and 
the speed of response may vary between different 
machines. For overnight pulse oximetry in sleep 
medicine, it is important that the oximeter is set to 
the shortest time interval for measurement; 5 s or less 
is regarded as being acceptable.
 ► External light interference: external light absorbed by the 
photodetector may alter the SpO2, for example, fluo-
rescent light, sunlight and overhead lights in theatre. 
Correct probe positioning and covering the probe 
with an opaque material will help eliminate external 
light interference.
 ► Substance interference: skin pigmentation may affect 
readings as calibration curves have usually been 
established using Caucasian subjects. Nail polish 
(especially green, blue and black) and synthetic nails 
may affect the accuracy of pulse oximeters as they 
are likely to cause a reduction in SpO2 reading. Nail 
varnish and false nails must be removed before the 
pulse oximeter probe is applied to the finger. Intra-
venously administered dyes, for example, methylene 
blue and fluorescein (orange colour), may decrease 
the measured SpO2.
 ► CO and methaemoglobin: the wavelengths of light used 
in the process of estimating SpO2 are unable to distin-
guish three or more forms of Hb. In the presence 
of COHb, for example, in heavy smokers or patients 
with acute CO poisoning, the SaO2 will be overesti-
mated. In the presence of methaemoglobin concen-
tration, SpO2 measured by oximetry will plateau at 
around 85% regardless of whether the true SaO2 is 
much higher or lower.
 ► Anaemia: anaemia can affect the accuracy of pulse 
oximetry since the reading depends on the light 
absorption of Hb. When Hb amount is reduced, this 
has a direct effect on the measurement obtained.
respIrAtory muscle Assessment
Introduction
The scope of this section is limited to non- invasive tests 
of respiratory muscle function and associated pulmonary 
function tests which may suggest the presence of respira-
tory muscle weakness. All the tests described could be 
undertaken within a clinical physiology department.
Direct assessment of respiratory muscle strength 
cannot be performed; however, methods based on 
measuring the pressure- generating capacity of the respi-
ratory muscles have been developed. Simple non- invasive 
volitional manoeuvres can be undertaken to determine 
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the absence, rather than the presence, of profound 
respiratory muscle weakness and so avoid the necessity 
of further complex, invasive, non- volitional tests, which 
may be needed to elucidate and diagnose true respira-
tory muscle weakness.
equipment
Measurements of airway pressures are used to provide a 
surrogate index of respiratory muscle output rather than 
directly measuring respiratory muscle contractile prop-
erties. Pressures measured during volitional manoeuvres 
reflect the synergistic action of several respiratory muscle 
groups, whereas those produced by motor nerve stimu-
lation reflect the contractility of the individual muscles 
under investigation, for example, phrenic nerve stimula-
tion to assess diaphragm function.
The ATS/ERS have jointly published guidelines 
describing the appropriate characteristics for equipment 
required to measure respiratory muscle function.116 
When measuring maximum inspiratory and expiratory 
pressures generated during volitional manoeuvres, a 
pressure transducer with a resolution of approximately 
0.05 kPa (0.5 cmH2O) and a range of up to ±20 kPa (±200 
cmH2O) should be sufficient. Transducers should have a 
flat frequency response up to 15 Hz. Validation to ensure 
linearity across the entire operating range should be 
performed regularly. This should be performed with the 
tubing and any additional fittings connected as these can 
significantly affect transducer performance. This is of 
particular relevance when measuring sniff nasal inspira-
tory pressure (SNIP) due to rapid pressure changes that 
occur during the manoeuvre.
A visual display of the pressure waveform produced 
during the manoeuvre is advantageous as visual inspec-
tion can help ensure the manoeuvre has been performed 
correctly. This is of particular relevance for sniff pressures 
when a short sharp effort is required to produce a rapid 
pressure spike which conforms to the recommended 
characteristics. The sampling frequency of the recording 
system should be at least 100 Hz to provide an accurate 
representation of the generated pressure.
Measurements of respiratory muscle strength are gener-
ally unfamiliar manoeuvres, so an experienced operator 
should provide careful instructions and a demonstration 
of the test procedure, as well as provide encouragement, 
motivation and feedback in order to obtain the best 
results.
maximal static inspiratory and expiratory pressures
Maximal static inspiratory pressure (PImax) and 
maximal static expiratory pressure (PEmax) (referred 
to as maximal inspiratory pressure and maximal expir-
atory pressure in older literature) performed at FRC 
reflect the pressure generated by the respiratory muscles 
alone. Manoeuvres performed at RV for PImax or TLC 
for PEmax also reflect the significant additional contri-
bution from lung and chest wall recoil. Although this 
contribution can be significant if weakness is present, 
clinical measures and normal values of PImax and PEmax 
do not conventionally correct for respiratory system 
recoil. Many reference ranges for PImax were developed 
in healthy subjects performing the manoeuvre from FRC 
rather than towards RV despite clinical testing, requiring 
the patient to exhale fully before performing a maximal 
inspiratory effort.
Patients generally find it easier to perform PImax 
from RV and PEmax from TLC, and adopting such an 
approach helps to standardise measurement. In addition 
the force- generating capacity of the respiratory muscles 
is directly influenced by the lung volume at which the 
test is performed as this will directly affect the operating 
length of the muscles themselves. In addition, despite 
tests being performed at fixed lung volumes, these may 
not completely represent isometric conditions, and gas 
compression and rarefaction result in muscle shortening 
or lengthening, and changes in muscle force–velocity and 
force–length relationships.117–119 Despite the complex 
relationship between respiratory muscle force genera-
tion and the pressure produced in the thorax or mouth 
and the varying contribution of the muscle force–length 
relationship and lung and chest wall recoil, PImax and 
PEmax reflect global respiratory muscle strength.
equipment
Self- contained electronic devices with either a digital 
display or computer display are commercially available. 
The ATS/ERS statement116 recommends a short rigid 
tube connected to a valve which allows the manoeuvre 
to be performed and the mouthpiece occluded following 
a short period of normal breathing. The device should 
contain a small air leak (2 mm internal diameter and 
20–30 mm in length) to prevent glottis closure during the 
PImax manoeuvre and prevent the patient from gener-
ating pressure using their cheek muscles during the 
PEmax manoeuvre. A flanged mouthpiece is generally 
recommended due to their ease of use by patients and 
the ability to form a leak- free seal. The type of mouth-
piece employed can significantly affect the pressure 
generated,120 particularly PEmax, although it is felt to be 
of little significance in clinical testing.116
Patients with severe orofacial muscle weakness may be 
unable to form a leak- free seal using a standard mouth-
piece and a face mask interface may be used. A tube inter-
face, consisting of a large diameter rubber tube pressed 
firmly against the face around the lips, may be used in 
patients who do not have respiratory muscle weakness 
but who break the seal around a mouthpiece or face 
mask during the manoeuvre, most commonly during the 
PEmax manoeuvre.120 121 Reference ranges are available 
for both the flanged mouthpiece and tube interface.116 122
test performance
With the patient seated and wearing a noseclip, they should 
be instructed to seal (pinch) their lips firmly around the 
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Figure 18 Maximum static mouth pressure traces. Mouth pressure versus time during maximal expiratory and inspiratory 
manoeuvres against an obstructed mouthpiece. Maximum pressure is sustained for approximately 3 s. PEmax and PImax 
measured as mean pressure over 1 s around peak pressure. Adapted from the American Thoracic Society/European 
Respiratory Society statement, 2002.120Reproduced from Hughes, ‘Physiology and Practice of Pulmonary Function’, 
published by the Association for Respiratory Technology & Physiology. PEmax, maximal static expiratory pressure; PImax, 
maximal static inspiratory pressure; RV, residual volume; TLC, total lung capacity.
Table 7 Regression equations used to calculate mean 
values and LLN for PImax and PEmax
Reference values Mean (cmH2O)* LLN (cmH2O)*
Male PImax 120 − (0.41×age) 62 − (0.15×age)
Male PEmax 174 − (0.83×age) 117 − (0.83×age)
Female PImax 108 − (0.61×age) 62 − (0.50×age)
Female PEmax 131 − (0.86×age) 95 − (0.57×age)
For male and female PImax the weighted means of the slopes and 
intercepts for flange mouthpiece data of Hautmann et al134 and 
Windisch et al.135 Male PEmax used the weighted means of the 
slopes and intercepts for flange mouthpiece data from Vincken et 
al.136 Wilson et al137 and Neder et al.138 Female PEmax used the 
data from Neder et al.138 (table 8)
*To convert cmH2O to kPa, multiply by 0.0980665.
LLN, lower limit of normal; PEmax, maximal static expiratory 
pressure; PImax, maximal static inspiratory pressure.
mouthpiece. If a good seal is hard to obtain, either the 
patient or the operator can use their hands to press the 
lips against the mouthpiece during each manoeuvre.123 
Alternatively, a face mask interface or tube mouthpiece 
(as described in the equipment section above) can be 
used. If a satisfactory seal cannot be achieved, an alter-
native test of respiratory muscle strength such as SNIP 
should be used.
 ► PImax: the patient should be instructed to exhale 
slowly and fully to RV and then perform a sustained 
maximum inspiratory effort against the occlusion. It 
has been described to patients as ‘sucking in hard, 
like trying to suck up a thick milkshake through a 
straw’.
 ► PEmax: the patient should be instructed to inhale 
fully to TLC and then perform a sustained maximum 
expiratory effort against the occlusion. It has been 
described to patients as ‘blowing up an uninflated 
party balloon’.
The patient should be encouraged to maintain pres-
sure generation for a minimum of 1.5 s, as estimated by 
the operator, and the largest negative (PImax) or positive 
(PEmax) pressure sustained for at least 1 s (not a transient 
spike) is recorded figure 18.116 The patient should be 
allowed to rest for approximately 1 min between manoeu-
vres and the manoeuvre repeated until the operator is 
confident a maximal manoeuvre has been performed,116 
which may need five or more attempts.124 125 The largest 
value for PImax and PEmax should be reported along-
side the predicted value and the lower limit of the normal 
range (table 7). At least three additional measures should 
be performed if the last measurement was the largest of 
the testing session or if the second largest measurement 
was less than 90% of the largest. The operator should aim 
for the variability across measurements to be less than 
1 kPa (10 cmH2O)
124 or less than 20% across the largest 
three values.116 In general approximately 85% of healthy 
adults achieve less than 1 kPa difference between meas-
urements.126 127 Because the tests require volitional effort, 
it is good practice to report the degree of patient cooper-
ation and effort alongside the test results.
sniff nasal inspiratory pressure
SNIP is a non- invasive test of inspiratory muscle strength 
requiring the patient to perform a short, sharp sniff, 
during which nasal inspiratory pressure is measured 
by means of a bung inserted in one nostril connected 
by a catheter to a suitable pressure transducer. As the 
test involves a simple natural manoeuvre, it is relatively 
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Table 8 Mean reference values and LLN for SNIP
Reference values Mean (cmH2O)*
SEE 
LLN=mean−
(SEE×1.645)
Male SNIP (−0.42 × age) + 126.8 SEE=23.8
Female SNIP (−0 22 × age) + 94.9 SEE=17.1
Mean reference values and LLN for SNIP in men and women using 
the regression equations. Men: y=−0.42 age + 126.8, SEE=23.8; 
women: y=−0 22 age + 94.9, SEE=17.1, as determined by Uldry 
and Fitting.135 The LLN is determined by subtracting the SEE × 
1.645.
*To convert cmH2O to kPa multiply by 0.0980665.
LLN, lower limit of normal; SEE, standard error of estimate; SNIP, 
sniff nasal inspiratory pressure.
easy for patients to achieve maximal efforts with a little 
practice. The most patent nostril for testing is selected 
by asking the patient to sniff while occluding alternate 
nares.
SNIP generally produces pressures in excess of those 
obtained during a PImax manoeuvre.128 The nose acts 
like a Starling resistor with flow through the unoccluded 
nostril remaining low during SNIP and independent 
of driving pressure. In severe airways obstruction pres-
sure, transmission through the lungs to the nose may be 
impeded,129 but otherwise the pressure measured in the 
nostril closely reflects intrathoracic pressure and inspira-
tory muscle strength.120 130
equipment
Self- contained electronic devices with either a digital or 
computer display are available. Sniff bungs of different 
sizes are available commercially. A sensitive transducer 
(resolution of approximately 0.05 kPa (0.5 cmH2O) 
and a range of up to ±20 kPa (±200 cmH2O)) with a flat 
frequency response up to 15 Hz, with the SNIP bung and 
tubing attached, should be used. Validation to ensure 
linearity across the entire operating range should be 
performed regularly.
performance
Prior to testing the patient should be asked about nasal 
patency and upper airway obstruction relevant to perfor-
mance of the SNIP test. Clearing any nasal congestion 
by blowing the nose prior to testing can help improve 
test performance. With the patient seated comfortably 
and the sniff bung wedged firmly in a patent nostril, they 
should be instructed to make short, sharp, maximal sniffs 
through the unoccluded nostril, starting from relaxed 
end expiration (FRC) with the peak pressure being meas-
ured for each attempt. Suitable sniffs for analysis show a 
regular upstroke on the pressure trace and sharp peak 
and total sniff duration of less than 0.5 s.131 As the sniff 
is a natural manoeuvre, it can be performed easily, and 
reproducibly, by most patients with little practice. Most 
patients are able to achieve a maximal effort with encour-
agement from the operator in less than 10 attempts. At 
least three additional measures should be performed if 
the last measurement was the largest of the testing session 
or if the second largest measurement was less than 90% 
of the largest. The largest peak pressure for SNIP should 
be reported alongside the predicted value and the lower 
limit of the normal (see table 8).
Interpretation
These tests are volitional requiring patient motivation 
and cooperation and can exclude clinical respiratory 
muscle weakness if pressures within the normal range 
are achieved. Low pressures may reflect either muscle 
weakness or poor test performance. Tests of respiratory 
muscle strength such as PImax, PEmax and SNIP used 
in isolation tend to overdiagnose weakness. Multiple tests 
of respiratory muscle function increase both diagnostic 
precision and make assessment possible in a range of 
clinical circumstances.132 It is best practice when assessing 
inspiratory muscle strength to perform both PImax and 
SNIP measurements. If low values are obtained then 
referral for advanced testing at a specialist centre should 
be considered.
reference ranges
The normal ranges are wide, so that values in the lower 
quarter of the normal range are compatible both with 
normal strength and with mild or moderate weakness. 
The ATS/ERS statement on respiratory muscle testing116 
indicates that significant respiratory muscle weakness is 
excluded if PImax reaches −8 kPa (−80 cmH2O), or if 
PEmax exceeds 8 kPa (80 cmH2O) for males, or 6 kPa 
(60 cmH2O) for females, or SNIP reaches −7 kPa (−70 
cmH2O) in males or −6 kPa (−60 cmH2O) in females. 
A normal PEmax with a low PImax suggests isolated 
diaphragmatic weakness.
Evans and Whitelaw133 reviewed the available data and 
compiled estimated mean reference values and lower 
limits of normal for PImax and PEmax (table 7) that 
demonstrate the normal age- related decline of maximal 
respiratory pressures and sex differences. Male and 
female data are reported separately, with male exceeding 
female values for PImax by 34%–66% and PEmax by 
41%–57%, depending on age. Age also correlated with 
respiratory muscle strength and was therefore used as the 
independent variable in prediction equations.
For male and female PImax the weighted means of 
the slopes and intercepts for flange mouthpiece data 
of Hautmann et al134 and Windisch et al.135 Male PEmax 
used the weighted means of the slopes and intercepts for 
flange mouthpiece data from Vincken et al,136 Wilson et 
al137 and Neder et al.138 Female PEmax used the data from 
Neder et al.138
PImax, SNIP and PEmax can reliably track change 
in respiratory muscle strength139 and guide clinical 
management.140–144 Based on data from studies in healthy 
subjects,145 a change of more than 2.5 kPa (25 cmH2O) 
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Figure 19 A comparison of reference equations.176 (Top) An amalgamation of the Rosenthal (paediatric) and the European 
Community for Coal and Steel (adult) equations. (Bottom) The multiethnic Global Lung Initiative equations. Source: ARTP 
Practical Handbook of Spirometry.176 FEV1, forced expiratory volume in 1 s.
can be used as the threshold to identify true change in 
respiratory muscle strength. No correlation has been 
observed between smaller improvements in PImax or 
PEmax and symptoms.146–148
erect versus supine vc
A reduced VC is common in respiratory muscle weakness 
and reflects both inspiratory and expiratory weakness, 
preventing full inflation and expiration, respectively, 
as well as reduction in lung and chest wall compliance, 
which are observed in patients with chronic respiratory 
muscle weakness.149 150 The change in VC is however less 
sensitive than PImax, SNIP and PEmax in mild weak-
ness.151 In adults a fall in VC greater than 30% when 
supine compared with the upright posture is indicative of 
isolated or disproportionate diaphragm weakness.152 The 
marked change in VC is a result of the action of gravity 
on the abdominal contents and the change in diaphragm 
geometry and load. The change in VC from standing to 
supine in healthy subject is approximately 5%–10%.153
performance
The procedure is not particularly well defined, but the 
patient should be fully supine; however, this will depend 
on how well the patient can tolerate this posture due to 
orthopnoea. Semirecumbency may be a better approach 
under such circumstance, but this should be recorded.
specialist respiratory muscle function tests
Sniff oesophageal pressure is a test that is only carried 
out in more specialist centres but is recognised as the 
best overall volitional measure of inspiratory muscle 
strength.154 This is an invasive test with discomfort from 
swallowing an oesophageal balloon. Sniff transdiaphrag-
matic pressure can be obtained in a similar manner using 
a second pressure catheter located in the stomach to 
provide a measure of abdominal pressure. Measuring the 
gastric pressure during a maximal cough reflects expira-
tory muscle strength and better discriminates expiratory 
muscle weakness141 than PEmax. The transdiaphragmatic 
pressure can be elicited by unilateral or bilateral electrical 
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Table 9 Summary of lung function reference equations recommended for use in paediatrics
Index Author (reference)
Population
(age range/ethnicity/sample size) Limitations for a UK population
Spirometry FEV1, FVC
FEV1/FVC
FEF75
FEF25–75
FEV0.75 and 
FEV0.75/FVC—in 
children aged 
3–7 years
Quanjer et al44 >74 000 healthy non- smoking 
subjects 3–95 years.
5 ethnic groups: Caucasian; Black 
American; South East Asian; North 
East Asian; Other/Mixed.
No published data on the Indian 
subcontinent.
No predicted values for PEF.
Gas transfer TLco
VA
Kco
Stanojevic et al
47
(~2000 subjects <19 years) Healthy 
non- smoking subjects, 4–91 years.
Limited use in non- Caucasians.
Plethysmographic 
lung volumes
FRC
TLC
RV
Rosenthal et al160 772 (455 male) Caucasian children 
aged 4–19 years, included pubertal 
assessments.
Have pubertal breakpoints.
Based on just height, thus does 
not appropriately predict for 
those short- for- age.
Respiratory 
muscles
SNIP Rafferty et al or
Stefanutti et al162 163
Rafferty et al: 116 children from a 
single school, multiethnicity, aged 
4–11 years (54 girls)
Stefanutti et al: 180 Caucasian 
children (93 boys).
Limited sample size (Rafferty et 
al).
Limited use in non- Caucasians 
(Stefanutti et al).
  MIP/MEP Lanza et al or ATS/
ERS statement 
2002116 177
Lanza et al: 450 Brazilian children 
(238 girls).
ATS/ERS: multicentre study.
Lanza et al: not validated in a UK 
population.
It is important to liaise with your local manufacturer to ensure you have the most appropriate prediction module installed for your 
population.
It is recommended that you regularly check for updates of reference equations with the ARTP Paediatric and Standards Committee and 
at the GLI website: http://www.ers-education.org/guidelines/global-lung-function-initiative.aspx.
ARTP, Association for Respiratory Technology & Physiology; ATS, American Thoracic Society; ERS, European Respiratory Society; FEF, 
forced expiratory flow; FEV1, forced expiratory volume in 1 s; FRC, functional residual capacity; FVC, forced vital capacity; GLI, Global 
Lung Function Initiative; Kco, gas transfer coefficient for carbon monoxide; MEP, maximal expiratory pressure; MIP, maximal inspiratory 
pressure; PEF, peak expiratory flow; RV, residual volume; SNIP, sniff nasal inspiratory pressure; TLC, total lung capacity; TLco, carbon 
monoxide transfer factor; VA, alveolar volume.
or magnetic phrenic nerve stimulation providing a non- 
volitional but invasive and unpleasant measure of inspir-
atory muscle contractility.155 156 Additionally recording 
the diaphragm electromyogram using an oesophageal 
electrode catheter allows phrenic nerve and diaphragm 
function to be assessed.157
Although PImax, PEmax and SNIP provide easily appli-
cable tests of respiratory muscle strength, such tests are 
volitional and should be best viewed as simple screening 
tools. Clinical weakness can be excluded if high pressures 
within the normal range are achieved. Low pressures are 
difficult to interpret, indicating either muscle weakness, 
poor test performance or the impact of pulmonary func-
tion; airway pressure measurements during dynamic 
manoeuvres such as sniff may be affected by airway 
calibre resulting in poor pressure equilibration across the 
lung to the upper airway. PImax, PEmax and SNIP used 
in isolation therefore tend to overdiagnose weakness.
It is therefore best practice when assessing inspira-
tory muscle strength to perform both PImax and SNIP 
measurements.132 If low values are obtained then referral 
for advanced testing at a specialist centre should be 
considered.
PImax SNIP and PEmax may be more reliable when 
tracking change by regular, repeated testing.139 A change 
of more than 25 cmH2O can be used as the threshold to 
identify true change in respiratory muscle strength.145
In addition to the usual contraindications (see ‘Contra-
indications for lung function testing’ section), there are 
also conditions where suboptimal performance of voli-
tional tests of respiratory muscle strength is likely:
 ► Chest or abdominal pain of any kind.
 ► Oral or facial pain exacerbated by a mouthpiece.
 ► Stress incontinence.
 ► Dementia or confused state.
 ► Chest infection or acute exacerbation of lung disease.
pAedIAtrIc lunG FunctIon testInG
Paediatric lung function testing is often as much an art 
as it is a science to perform. Routine lung function meas-
urements can now be performed in paediatrics from the 
age of 3 years through to the age of 16–18, where they 
are commonly seen in adult physiology services. This age 
range encompasses a large and dramatic change in both 
the lung physiology and the cognitive development of 
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the child. Paediatric services therefore need to be able to 
adapt to these complexities.
When assessing children, attention should be given to 
the suitability of different tests compared with the cogni-
tive development of the child. Spirometry can often be 
successfully performed from the age of 3 years when 
assessed in the appropriate environment with trained 
clinical physiologists, and attempting spirometry from a 
young age is encouraged, particularly if regular follow- up 
is required. Other tests are more complex and there-
fore may need greater cognitive awareness. Gas transfer 
and lung volumes should be considered from the age 
of 7 years, while acknowledging that some children will 
need to be older to obtain successful measurements and 
some will be capable at an earlier age. Age should always 
be documented to one decimal place to minimise error 
in relation to reference values.44
Physiologists working with children should be experi-
enced in doing so and should demonstrate enthusiasm 
and patience with the children in order to obtain the best 
results for them. In services where both adults and chil-
dren are routinely assessed, specific staff members should 
be responsible for paediatric testing, and ideally there 
should be a child- friendly environment. These physiolo-
gists should gain specific experience in dedicated paedi-
atric laboratories and attend paediatric- specific courses if 
experience of paediatric testing is required.
The environment in which children are tested should 
be suitable for children of all ages. The room should 
be bright and decorated in a child- friendly manner. It 
should contain suitable distractions such as books and 
toys and with incentives, such as stickers, available for 
reward. Child- specific patient leaflets should be used and 
should be appropriate for the age of the child as well as 
the child’s parents/carers. Children should not be tested 
alongside adult patients.
When testing young children in particular, the tests 
should be considered a game or a challenge, with every 
test seen as a success regardless of the technical quality or 
clinical outcome of the test. This approach emphasises 
testing as a positive and allows young children to engage 
with the testing session. As a result, testing sessions need 
to be longer than for adults to allow for the extra time 
needed to engage the child, for example a time slot of 
1 hour is required for assessing spirometry, gas transfer 
and lung volumes in children younger than 12 years of 
age.
Care should be taken to accurately measure height in 
centimetres (barefoot) and weight in kilograms (after 
removing outer garments) and be documented to 
one decimal place. The rapid rate of growth of a child 
requires this information to be reassessed at every visit. 
For patients where measuring height is inappropriate/
unfeasible, for example wheelchair users or those with 
spinal deformities, either an accurate measure of arm 
span or ulna length can be used as a surrogate. There 
are published reference data for the use of both of these 
measurements as a substitute for standing height.14 158 
Caution should be applied when using arm span as a 
direct substitute for standing height as recent evidence 
suggests that the ratio between arm span and standing 
height varies throughout childhood and across different 
ethnicities.14 Technical comments should be available 
on the report when a substitute for height is made, for 
example: ‘Predicted values are calculated from standing height 
but since we were unable to obtain accurate measurements of 
standing height arm span/ulna length were used to estimate 
height. Interpret results with caution’.
paediatric spirometry
The spirometry test protocol is very similar to adults: It 
should be performed with the child wearing a noseclip 
and seated in an adjustable chair ensuring the child’s feet 
can touch the floor. There should be a minimum of three 
attempts; however, since children often need several 
attempts to perfect the technique and do not fatigue 
as readily as adults, there should be no set number of 
maximum attempts. Young children often have to 
perform >10 attempts to achieve repeatable results. In 
order to ensure the child maintains concentration levels, 
there should be no minimum wait time between succes-
sive attempts.
Start of test criteria for older children (>6 years) is 
similar to adults with a back extrapolation volume of 
<5% of FVC or 100 mL, whichever is the greater. However, 
in preschool children (<6 years), due to increased relative 
lung volume to airway size, back extrapolation criteria 
is more lenient with an absolute back extrapolation of 
<75 mL or 10% of FVC, whichever is the greater.159 There 
is no minimum forced expiratory time requirement in 
children. Younger children will empty their lung volume 
rapidly, with preschool children often completing exhala-
tion in <1 s. A volume plateau on the volume–time graph 
can assist in determination of successful end of forced 
expiration. The exception to this is in preschool chil-
dren, where lung emptying is rapid, when the end of test 
criteria is successful if the volume curve is approaching 
a plateau on the volume–time graph. It is important to 
note that practice attempts should not be discarded and 
all efforts recorded within the software of the equipment. 
For paediatric spirometry, repeatability of FEV1 and FVC 
differs for preschool and school- age children. In all chil-
dren the child should ideally perform at least three tech-
nically acceptable attempts, but results should not be 
discarded if this is not the case. In school- age children 
the highest and second highest values for FEV1 and FVC 
should be within 100 mL or 5%, whichever is the greater 
value, while for preschool children this value should be 
100 mL or 10%, whichever is greater.
In paediatric spirometry visual feedback incentives 
or games must be available in order to aid the child to 
perform the test correctly. Visual incentives can also 
help sustain the expiratory effort to achieve the best 
FVC. Ideally the games should be manually adjustable to 
enable the difficulty to be adjusted to ensure the operator 
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can achieve the desired outcome with each child. The 
use of these incentives helps ensure that the spirometry 
session is seen more as a ‘game’ than a ‘test’.
The display should have a zoom capability to view 
results from young children appropriately.
The reporting of spirometric values should follow that 
of adult guidelines with the best FEV1 and FVC reported 
from all accurate measured attempts with flow data 
reported from the flow volume loop with the greatest 
sum of FEV1+FVC. FEV1 should not be reported if the 
forced expiratory time is <1 s, using the FEV0.75 instead. 
In this circumstance the ratio of FEV0.75/FVC should be 
used to define airflow obstruction using the GLI 2012 
LLN for this index.44 Technical comments on the accept-
ability and repeatability should always be included in the 
report, particularly when the technique is suboptimal.
In the assessment of bronchodilator response, the stan-
dard procedure should be to administer 400 µg of salbu-
tamol via a metered dose inhaler plus spacer device. A 
noseclip should be worn to ensure mouth breathing, and 
in younger children a face mask with the spacer may be 
required. The absolute change and percentage change 
from baseline should be reported.
paediatric static lung volumes
Body plethysmography is often the first method of choice 
when measuring static lung volumes in paediatrics for 
several reasons; it is well tolerated by children (>6 years) 
and several efforts can be made in a short space of time. 
Also the currently recommended reference data for 
paediatric lung volumes160 were performed using body 
plethysmography. In addition to lung volume measure-
ments, airway resistance can be easily measured in chil-
dren during the plethysmography protocol. This should 
be performed prior to FRC occlusions during initial tidal 
breathing and the child should be instructed to breathe 
tidally at 30–40 breaths per minute.161 If animations are 
available they can be used to facilitate obtaining this 
breathing frequency, otherwise the operator should 
guide the child’s respiratory rate.
A footrest should be available for children whose feet 
do not touch the floor. If this is required, the box cali-
bration should be performed with the step inside the 
box. Children often find it difficult to perform adequate 
relaxed VC manoeuvres and therefore forced manoeu-
vres can be considered.
paediatric single-breath gas transfer for co
The measurement of gas transfer in paediatric patients 
follows the same process as for adults. Measuring gas 
transfer in children is not part of ‘routine’ lung func-
tion assessments, but it is still an important clinical tool 
in certain patient groups frequently seen in specialist 
centres.
The complexity and practicalities of the single- 
breath technique mean that the measurement can be 
challenging in young children <6 years. If using slow 
responding gas analysers, some small children may not 
be able to exhale a large enough sample volume (1.2 L) 
to achieve a valid result. However, most children from 
age 6 to 7 years and onwards should attempt the measure-
ment if there is a clinical need. With fast responding gas 
analysers it is possible to determine lung gas transfer 
in subjects with a VC <1.2 L (see ‘Washout and sample 
collection’ section). Test performance is very similar to 
an adult patient; however, there is no need to emphasise 
a relaxed exhalation prior to inhalation of the gas mix. 
As mentioned in the ‘Spirometry’ section, many young 
children will be more likely to reach RV if they perform 
a forced manoeuvre. The other modification from the 
adult protocol is that the inspired volume threshold is 
lowered to be at least 85% of the measured VC.
Refer to ‘Measurement of carbon monoxide transfer 
factor’ section for more information on test protocol and 
quality control.
paediatric respiratory muscle testing
Assessment of respiratory muscle function in children 
involves an integrated approach using both direct and 
indirect tests of respiratory muscle function. The most 
common tests performed in children measure the 
pressures generated within the thorax during maximal 
‘sniffing’ (SNIP), inspiratory (PImax) or expiratory 
(PEmax) manoeuvres. All three of these tests require 
maximal effort and cooperation from the child to 
perform accurate manoeuvres; despite this, children as 
young as 4 years can perform maximal SNIP manoeuvres 
and can usually generate PImax and PEmax successfully 
from the age of 5–7 years.
SNIP reflects inspiratory diaphragmatic strength in 
children and should be used as the first- line test of inspi-
ratory respiratory muscle function. The technique is rela-
tively non- invasive and intuitive to young children and 
can be performed longitudinally to monitor the effects of 
progressive neuromuscular disorders such as Duchenne 
muscular dystrophy. It is performed using a pressure 
transducer attached to a nasal probe that is seated in one 
nostril. The ‘sniff’ manoeuvre is then performed through 
the unobstructed contralateral nostril by performing a 
maximal short ‘sharp’ sniff. Performing the manoeuvre 
from FRC rather than RV is more common in paediatric 
practice due to intuition; however, it is important to 
document which method is used and then to be consis-
tent for any longitudinal assessments as the two different 
lung volumes may produce differing results. It is not 
uncommon to perform >10 attempts in order to obtain 
accurate maximal efforts with efforts made through both 
nostrils to counter the effects of poor airflow through 
either nostril. The operator should aim to obtain accu-
rate maximal efforts aiming for the best two attempts 
agreeing within 10% of each other.
Paediatric reference equations available to assess 
abnormality are available.162 163 A SNIP value greater than 
the LLN rules out significant diaphragmatic weakness; 
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however, a low value is not diagnostic of weakness. In 
the case of a low value, a PImax manoeuvre should be 
performed if not already routine practice. A normal 
value in either of these measures can rule out significant 
inspiratory respiratory muscle weakness.
Indirect measures of respiratory muscle function also 
play a key role in assessment. These may include spirom-
etry, cough PEF, the monitoring of blood gases and 
the simple measurement of respiratory frequency and 
tidal volume. Spirometry, alongside tests such as SNIP, 
remains the key measurement of indirect muscle func-
tion and should be performed at every visit, as soon as 
the child is old enough. FVC and cough PEF in particular 
should be monitored longitudinally. An FVC of <1.1 L 
coupled with a cough PEF of <160 L/min is associated 
with an increased risk of severe chest infections in chil-
dren with neuromuscular disorders; however, caution 
should be applied when using these cut- offs as they do 
not consider the age/size of the child.164 Cough PEF 
should be performed routinely at each visit and measured 
using a fast- response pneumotachograph as opposed to 
a handheld PEF metre.165 Spirometry may also play a 
role in highlighting isolated diaphragmatic weakness by 
performing the test in supine position. A >25% reduction 
of VC in the supine position can be regarded as signifi-
cant for diaphragm weakness.166
In summary routine follow- up of children with neuro-
muscular disease should include at the least measures 
of spirometry, SNIP and cough PEF, with the addition 
of PImax and PEmax when needed. It is imperative that 
these results are plotted as trend data and interpreted in 
a longitudinal manner in known neuromuscular patients.
‘paediatric reference values’
Despite similar functions, the size, shape and composi-
tion of the respiratory system change dramatically from 
infancy to adulthood. At birth, all generations of the 
conducting and respiratory branches have been gener-
ated; however, it is estimated that only a third to half of 
the adult complement of alveoli are present at birth.167 
Consequently infants/young children have a large airway 
size relative to lung volume. Rapid increases in size and 
number of alveoli occur in infancy and early childhood, 
with lung function increasing 20- fold during the first 10 
years of life.168 During childhood, FVC outgrows FEV1, 
leading to decreases in FEV1/FVC, with these trends 
being reversed during adolescence.169 Accurate descrip-
tions of the ‘normal range’ need to take these physiolog-
ical factors into account if respiratory impairment is to be 
detected accurately.
The principles behind normative reference data are 
based on the theory that a summary measure of values 
obtained from ‘normal’ individuals will represent the 
range of values expected in a healthy population. A 
literature search on PubMed will reveal hundreds of 
paediatric reference equations relating to different 
populations, age groups and nationalities. Until recently, 
no lung function reference equation spanned the entire 
lifespan, with many focusing on discrete age groups (eg, 
preschool children (3–6 years), school- aged children 
(often commencing at 6–8 years of age and finishing 
at 16–18 years of age) or adults (some commencing at 
25 years of age)). This resulted in different reference 
equations being ‘stitched together’ so that a wider age 
range could be tested without the user needing to manu-
ally switch between equations when testing patients of 
different ages. However, arbitrary breakpoints between 
specific age groups can lead to serious misinterpretation 
of results, particularly when trending results over time in 
a growing child (figure 19).170
The all- age, multiethnic GLI spirometry reference 
equations44 should be used routinely for paediatric 
spirometry. The GLI equations offer a smooth transition 
across the ages (ie, no changes from paediatric to adult 
equations) and a well- defined LLN for all ages. Approx-
imately 30 000 out of the 74 000 subjects in the GLI data 
set were <20 years of age.
At the time of publication the GLI reference equations 
were only available for spirometry and gas transfer, with 
equations for static lung volumes expected in future 
publications. Table 9 summarises the reference equations 
that are most appropriate for the other paediatric lung 
function tests. It is unrealistic to expect a single set of 
reference data to include multiple lung function indices 
over the entire age range and for multiple ethnic groups. 
Therefore the most appropriate equations have been 
selected with the knowledge that the manufacturers of 
lung function equipment are able to develop appropriate 
‘prediction modules’ which represent the appropriate 
reference equation for each index. When interpreting 
lung function it is important to take into consideration 
the limitations of each reference equation and ensure, 
where applicable, these limitations are clearly docu-
mented on each report.
The GLI spirometry equations focused on indices 
recommended by the ATS/ERS guidelines (ie, FEV1, FVC, 
FEV1/FVC and FEF25-75)
3 and were only able to develop 
robust equations where there were sufficient data. PEF 
and FEFxx subdivisions were not included; however, there 
are several publications that have demonstrated that FEF 
does not offer any interpretative advantage over FEV1 
and FEV1/FVC.
171–173
The plethysmographic lung volume equations48 
suggested in table 9 are limited to Caucasian children, 
and caution should be applied when interpreting results 
from non- Caucasian children and those going through 
puberty or transitioning to adulthood.
All reports should state ethnicity and include a comment 
to state if results have been adjusted for ethnicity. Results 
should be interpreted using z- scores and the LLN as 
discussed in the ‘Reference values’ section. For the longi-
tudinal assessment of lung function tests, the absolute 
value alongside the z- score should be plotted over time. 
As children have a rapidly developing respiratory system, 
plotting the absolute values alone will not provide a 
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meaningful assessment of the z- score alongside the abso-
lute value allows for the current age and growth of the 
child to be considered.
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